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ABSTRACT 
 
Aim 
To determine the prevalence of depression amongst people with chronic obstructive 
pulmonary disease (COPD) on long term oxygen therapy (LTOT) and examine the 
differences and relationships between depressed and not depressed patients to inform 
clinical practice.  
Methods 
In September 2009 a cross-sectional point prevalence study of the total District Health Board 
(DHB) population of COPD patients on LTOT oxygen in a large urban area in New Zealand 
(NZ) was conducted. Depression was assessed using the self-completed Patient Health 
Questionnaire (PHQ-9). Additional clinical and demographic characteristics were obtained 
from hospital records and a self-completed questionnaire. 
Results 
Sixty three patients (36 females, mean age 72) from the total population of 73 with severe 
COPD (forced expiratory volume in one second [FEV1] 37% predicted) completed the 
survey. PHQ-9 results indicate the total prevalence of depression was 54%; 95% CI 41.71-
65.87. Twenty five percent of patients had mild depression and 29% had moderate to severe 
depression. One in six patients of those who screened positively was being treated for 
depression. No significant correlations or differences were found between the depressions 
scores and the demographic (age, gender, lives alone) or clinical (portable oxygen, time on 
oxygen, hospital admissions, pulmonary rehabilitation and FEV1) characteristics. 
Conclusion 
This study provides new evidence regarding the prevalence of depression in NZ COPD 
LTOT populations. Depression symptoms and depression are highly prevalent in this patient 
population and there is evidence depression is undertreated. The PHQ-9 is a simple and 
effective tool community nurses can use for the initial screening of depression, which could 
improve the recognition and possible uptake of effective interventions to lessen the impact of 
depression in this population. The PHQ-9 is validated screening tool that should be used in 
further depression prevalence research with NZ COPD and other long-term condition 
populations to determine homogeneity across studies. 
 
 
 
Key words: Chronic obstructive pulmonary disease, long term oxygen therapy, depression, 
prevalence, screening 
  ii
ACKNOWLEDGEMENTS 
 
To all the people that participated in this study, thank you for your wiliness and time. 
 
To the Capital & Coast District Health Board Community Health Service management and 
nursing staff, thank you for your support with data collection and interest in my research. 
 
To Kathy Nelson, my thesis supervisor: 
Your experience and guidance has been invaluable, thank you.  
 
To John, my husband: 
For your love and all the wonderful food you cooked me every night. 
 
To my children, Thomas and Caitlin thanks for being so awesome. 
 
To my good friends, Rebecca Missen, Rosalind Parry and Helen Costello, your support and 
encouragement has sustained me. 
 
  iii
 TABLE OF CONTENTS 
 
Abstract……………………….……………………………………………………………..ii 
Acknowledgments…….…….…………………………………………………………...iii 
Table of contents…….…….…………………………………………………………….iv 
List of figures………….….…….………………………………………………….……...v 
List of tables…………………………….…………………………………………………vi 
 
 Chapter 1 – Introduction…………………………………………....…...........…..1 
                           Background and significance of this research......................................................2 
    The burden of chronic obstructive pulmonary disease (COPD)...………..….…...2 
    Care context for people with COPD on long term oxygen therapy………...….....3 
                           Overview of thesis…………………………………………………………......…......4 
 
Chapter 2 – Clinical management of COPD ................................................ 5 
Definition and pathophysiology of COPD ............................................................ .5 
Overview of management goals in stable COPD ................................................. 6 
Oxygen therapy in COPD ..................................................................................... 7 
Adherence to recommended management in COPD ........................................... 8 
Pulmonary rehabilitation ....................................................................................... 8 
Patient-centred COPD management ................................................................... 9 
Impact of Depression ......................................................................................... 11 
Screening for depression in practice .................................................................. 12 
What the COPD guidelines say about assessing for depression ....................... 13 
Summary ............................................................................................................ 14 
 
Chapter 3 – Literature review ...................................................................... 15 
       Method ..................................................................................................... 15 
Search strategy .................................................................................................. 15 
Critical appraisal ................................................................................................. 15 
        Results and discussion .............................................................................. 16 
Overview of the literature ................................................................................... 16 
Systematic reviews ............................................................................................ 16 
Studies that utilised depression screening or diagnostic instruments ................ 18 
Population based studies ................................................................................... 22 
        Summary ............................................................................................................ 23 
 
Chapter 4 – Study methodology and design ............................................. 24 
       Aims and objectives ............................................................................................ 24 
       Background to the methodology and design ................................................ 24 
   Observational research foundations ............................................................ 25 
   Framework ................................................................................................ 25 
   Using this framework ................................................................................. 25 
       Ethics ...................................................................................................... 28 
   The methods .............................................................................................. 29 
   Study population ......................................................................................... 29 
  Data collection and measurement instruments .............................................. 30      
Procedure...................................................................................................31 
   Data analysis ............................................................................................ 32 
 
 
 
 
  iv
 
 
 
Chapter 5 – Results.......................................................................................33 
    Study population……………………………………………………………………...33 
        Patient characteristics……………………………………… …………………...….33 
        Overall descriptions…………………………………………………………...……..33 
        Responder’s additional descriptions………………………………………...……..34 
        Depression scores…………………………………………………………...………35 
        Predictors of depression..…………………………………………………...………37 
        Summary..………………………………………....................... ………...…...……38 
 
Chapter 6 – Discussion and conclusion.....................................................39 
        The main findngs……………………………………….……………......….............39 
        Demographic and clinical profiles…………………………………………………..39 
        Data collection....................................................................................................40 
        The findings compared.................………………………………………………….41 
        This study's strengths and limitations……...………………………………………44 
        Recommendations for research and practice.....................……………...………44 
        Conclusion…………………………………………………………………………….46 
 
Appendices………………………….………………………………………..……48 
    Appendix 1: Ethics approval…………………………………………………...……48 
        Appendix 2: Consent form………….........................……………………………...49 
        Appendix 3: Participant information sheet………………………………………....50 
        Appendix 4: General Practitioner letter……………………………………….…....52 
        Appendix 5: Whanau care letter…………………………………………………….53 
        Appendix 6: Developed participant questionnaire……………………….………..54 
        Appendix 7: The nine questions of the PHQ-9…………………………………… 55 
        Appendix 8: Coding sheet…………………………………..…………………….…56 
  
References .............................................................................................................. 57 
  v
  vi
 
LIST OF FIGURES 
 
Figure 1.1: Diagnosing and staging of COPD……………………………………......….2 
Figure 2.1: The cycle of physical, social and psychological costs of COPD….….......6 
Figure 2.2: CHS home services for respiratory related conditions.......………….........9 
Figure 5.1: Distribution of the PHQ-9 scores.............................................................37 
Figure 5.2: PHQ-9 total scores by gender…………………………………………........39 
 
LIST OF TABLES 
 
Table 3.1: Primary studies investigating the prevalence of depression in COPD......19 
Table 4.1: Demographic variables by name, description, values and type................32 
Table 4.2: Clinical variables by name description and type........................................32 
Table 5.1: Demographic and clinical characteristics of the responders and non-
responders...................................................................................................................35 
Table 5.2: Demographic and clinical features of the responders................................36 
Table 5.3: PHQ-9 scores and depression history of the responders..........................37 
Table 5.4: PHQ-9 severity scores and depression treatment.....................................38 
Table 5.5: Correlations between the PHQ-9 scores and the demographic and clinical 
characteristics.............................................................................................................38 
Table 5.6: Demographic and clinical factors that impact on depression....................38 
 
 
CHAPTER 1 – INTRODUCTION 
 
Studies and clinical practice confirm chronic obstructive pulmonary disease (COPD) 
is a variable yet generally progressive condition with pulmonary (i.e. airflow limitation 
and impaired gas exchange) and extra pulmonary effects (i.e. osteoporosis and 
depression) that cause sufferers significant morbidity and mortality (National 
Institutes of Health [NIH], 2007). The cardinal symptom of the reduced lung function 
is breathlessness, which leads people with COPD to reduce their activities, thereby 
becoming deconditioned and socially isolated. Impaired gas exchange late in the 
disease can lead to chronic hypoxia. The hypoxia can be partially treated, bringing a 
person’s blood oxygen level up (>60mmHg) with long term oxygen therapy (LTOT) 
thus preventing early organ damage and death and hopefully improving the person’s 
quality of life. This treatment requires adherence to a prescription of low flow oxygen 
administration delivered continuously, usually via an electric oxygen concentrator 
with long plastic tubing and nasal prongs which a person is connected to for over 15 
hours per day, for life. Living with the symptoms of COPD and the restrictions 
imposed by oxygen therapy potentially contributes to developing depression. 
 
This thesis reports on a cross-sectional point prevalence study examining the 
prevalence of depression amongst people with COPD on LTOT, in a large urban 
region in New Zealand (NZ), Wellington. Ethics approval for this study was granted in 
July 2009 by the Central Regional Ethics Committee (Appendix 1). This study’s 
primary aim was to determine the prevalence of depression amongst people with 
COPD on LTOT in a large urban area in NZ. The objectives were: 
• to describe the characteristics of depressed and non-depressed people (i.e. 
ethnicity, age gender, disease severity), thereby improving understanding 
about the occurrence and variation of depression prevalence for NZ people 
with COPD on long term oxygen therapy;  
• to inform the introduction of validated depression screening tool as standard 
in practice; 
• to inform future service provision for COPD LTOT patients in the community; 
and 
• to provide new knowledge of the prevalence of depression in the NZ COPD 
LTOT population and add to the total body of knowledge on the prevalence of 
depression in chronic obstructive pulmonary disease. 
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Depression is a common and treatable mental disorder (American Psychiatric 
Association [APA], 2000). There is considerable variability with regard to the reported 
prevalence, clinical recognition and access to treatment of depression for people with 
chronic obstructive pulmonary disease. Depression is characterised by changes in 
mood, thinking and activity, significant enough to impact on a person’s ability to take 
care of his or her everyday needs and responsibilities. Provision of timely diagnosis 
and treatment maybe assisted with the use of validated depression assessment tools 
for people with COPD in practice. 
 
Background and significance of this research 
The study was undertaken primarily to better understand the extent of depression in 
the COPD LTOT patient population. A critical examination of the published research 
about depression in COPD, identified gaps relating to the overall knowledge of the 
prevalence of depression for people with COPD on long term oxygen therapy. 
Specifically, no published studies conducted in NZ were found. This study’s findings 
will inform potential service improvements including: 1) increased accessibility to the 
types of services (i.e. pulmonary rehabilitation) offered for people with COPD on 
LTOT which are known to improve clinical outcomes, and 2) the decision to introduce 
the use of a validated depression screening tool as standard in practice with the aim 
of improving the identification, referral and uptake of treatments for depression in this 
population. 
The burden and classification of COPD  
The World Health Organisation estimates that COPD will be the fifth worldwide cause 
of disability adjusted life years lost and the third worldwide cause of mortality by 2020 
(Murray & Lopez, 1997). Currently COPD is the fourth leading cause of death in the 
world (NIH, 2007). In NZ COPD affects at least 200,000 people over the age of 45 
years. Based on NZ hospital admission data the prevalence of COPD for Māori is 
twice the rate for non-Māori; hospitalisation for Māori occurs at younger ages and the 
rate of admission increases more steeply with age than for non-Māori (Town, Taylor, 
Garrett, & Patterson, 2003). 
 
The diagnosis of COPD is based on a person’s history, symptoms and the 
documentation of a post bronchodilator spirometry forced expiratory volume in one 
second / forced vital capacity (FEV1/FVC) <70% and severity is staged as FEV1% of 
the predicted normal as shown in Figure 1.1. 
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Spirometry reference values are determined from the patient’s age, sex and height:  
1. Mild COPD FEV1/FVC < 0.70  
      FEV1 ≥ 80% predicted at this stage, the patient may not be aware that their lung function 
is abnormal. 
 
2. Moderate COPD FEV1/FVC < 0.70  
      50% ≤ FEV1 < 80% predicted symptoms usually progress at this stage, with shortness of 
breath usually developing on exertion. 
 
3. Severe COPD FEV1/FVC < 0.70  
     30% ≤ FEV1 < 50% predicted shortness of breath classically worsens at this stage and 
often limits patients’ every day activities. Exacerbations are especially seen beginning at 
this stage. 
 
4. Very Severe COPD FEV1/FVC < 0.70 
      FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure (need to 
consider assessment for oxygen therapy). At this stage, quality of life is very noticeably 
impaired and exacerbations may be life-threatening. 
 
 
Figure 1.1: Diagnosis and staging of COPD 
Adapted from: The Global Obstructive Lung Disease (GOLD) Spirometric Criteria for COPD 
Severity (National Institutes of Health, 2007). www.goldcopd.com/download.asp?intId=445  
 
 
Care context for people with COPD on long term oxygen therapy 
In the Wellington region Capital & Coast District Health Board (C & C DHB) 
Community Health Service (CHS) provide long term oxygen therapy. The CHS is 
joined to the local hospital and delivers ‘home care’ services to people with COPD on 
LTOT who meet the clinical criteria for LTOT; these will be described in Chapter 2. 
Home care covers people living in their own homes and rest homes and generally 
excludes those living in residential hospital level care facilities that are contracted by 
the DHB to provide 24/7 nursing cover. The services provided by CHS are covered 
under the publically funded NZ health system and so people are not selected under 
any financial or social basis. The DHB serves a regional population of about 250,000 
(http://www.ccdhb.org.nz/aboutus/Who.htm).  
 
The community health nursing service employs 53.8 full time equivalent nurses who 
see over 6000 people per annum with acute, chronic and palliative care needs (Mold 
& Boland, 2009). The average annual visits per person seen by this service are 14; 
totalling over 80,000 community nursing visits per year. At any given time there are 
up to 140 people on LTOT under the care of the community health nursing service 
and approximately 60% of these will have chronic obstructive pulmonary disease. 
 
I (the researcher) am the Respiratory Clinical Nurse Specialist for the Community 
Health Services. This role involves strategic and service planning, teaching, quality 
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components and the assessment and care of patients with respiratory conditions (in 
the main COPD) requiring specialist community nursing follow-up across the region. 
The service receive referrals from both primary and hospital settings. Within the CHS 
team I oversee the provision of oxygen and provide clinical expertise to the district 
nursing team regarding assessment, management and support of people receiving 
long term oxygen therapy. The set-up, routine assessments and afterhours support 
for people on LTOT is provided by the district nurses. The district nurses assisted 
with the data gathering of the research. 
 
Overview of thesis 
This introductory chapter has provided an overview of the context and background to 
this point prevalence study. 
 
Chapter 2 presents an in-depth explanation of interrelated pathophysiology, 
symptoms and current best practice considerations in the clinical management of 
people with chronic obstructive pulmonary disease and depression. 
 
Chapter 3 details and critiques the literature reviewed related to the overall current 
knowledge about the prevalence of depression for people with COPD on long term 
oxygen therapy. Specifically two similar studies are discussed in depth, guiding the 
rationale for the design of this study. 
 
Chapter 4 details this study’s observational research methodology, the sample, data 
collection method, data analysis and the steps taken to ensure the study’s reliability 
and validity. 
 
In Chapter 5 the results are presented. In addition to the depression score results, 
the chapter presents the findings concerning representativeness of the responders.  
 
Chapter 6 discusses the findings in relation to the literature and clinical practice. 
Explanations are given for expected and unexpected results. The research design, 
processes and limitations are also discussed. Recommendations are provided for 
practice and future research. 
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CHAPTER 2 – CLINICAL MANAGEMENT OF CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (COPD) 
 
This thesis reports on a study designed to examine the prevalence of depression in 
chronic obstructive pulmonary disease (COPD) patients on long term oxygen therapy 
(LTOT) in a large urban area in New Zealand. This chapter provides a contextual in-
depth explanation of the interrelated pathophysiology, symptoms and the current best 
practice considerations in the holistic clinical management of people with chronic 
obstructive pulmonary disease. 
Definition and Pathophysiology of COPD 
A frequently occurring and mainly non-reversible chronic lung disease; COPD is a 
complex of different pathophysiologies and clinical presentations, typically 
emphysema and chronic bronchitis. COPD is characterised by obstruction of lung 
airflow which interferes with normal breathing. The generally progressive history of 
COPD results in the widely recognised distressing symptoms of dyspnoea, chronic 
cough and sputum production. Figure 2.1 shows a simplified cycle of the individual 
effects often seen in this progressive condition. The most disabling symptom 
dyspnoea is experienced first with exercise (leading to reducing activities) and in 
severe disease with rest. In severe COPD, multi-system effects are evident and 
include malnutrition and muscle wasting which result in further dyspnoea and fatigue 
leading to significant deconditioning, increased exacerbations, anxiety and 
depression. Pulmonary hypertension and cor-pulmonale may also develop in 
advanced disease (NIH, 2007; O’Donnell, Revill, & Webb, 2001). 
 
COPD symptoms typically arise from cigarette smoking which causes abnormal lung 
inflammation in susceptible people. This abnormal inflammatory response produces 
the physiological changes characteristic of COPD. These include mucus 
hypersecretion, ciliary dysfunction, airflow limitation, hyperinflation and impaired gas 
exchange. It is thought hyperinflation develops early in the disease and is the key 
mechanism behind exertional dyspnoea (NIH, 2007). In general, gas exchange 
worsens as the disease progresses and can result in hypoxemia and hypercapnia 
(respiratory failure). The development of respiratory failure is indicated by oxygen 
tensions (Pa02) <60mmHg with or without carbon dioxide tensions (PaC02) > 
45mmHg taken as an arterial blood gas (ABG) while breathing air. Clinical signs of 
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respiratory failure or right sided heart failure include ankle swelling, increased jugular 
venous pressure (JVP) and central cyanosis (Brashers, 2002; NIH). 
                       COPD   
 
Reduced 
fitness  
 
Social 
isolation 
Depression Reduced 
mobility 
(Deconditioned)
Dyspnoea 
 
 
Figure 2.1: The cycle of physical, social and psychological costs of COPD 
Adapted from: Global Initiative for Chronic Obstructive Lung Disease (National Health 
Institutes, 2007). www.goldcopd.com/download.asp?intId=442   
 
Chronic hypoxemia causes pulmonary vasoconstriction and subsequently pulmonary 
hypertension with increasing strain and finally failure of the right ventricle (cor-
pulmonale). Secondary polycythemia may develop and cause increased viscosity. 
Other organ systems are also affected in particular those with high metabolic 
demands such as brain, skeletal muscle and kidney (McKenzie et al., 2008). 
Overview of management goals in stable COPD 
COPD is a heterogeneous disease influenced by continued exposure to risk factors 
(i.e. occupational or smoking), the rate of exacerbations and co-morbid illness which 
affect individual patients in different ways. Management includes pharmacological 
and non pharmacological interventions which need to be individually guided to cover 
the impairments, disability and handicap of the primary disease and co-existing 
conditions (National Institute for Clinical Excellence [NICE], 2004). The outcomes 
aimed for in the management of COPD are symptom relief, improved quality of life, 
through improved functioning, prevention and treatment of exacerbations and 
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complications, and reduced mortality (Celli et al., 2004; McKenzie et al., 2008; NIH, 
2007).  
 
To date smoking cessation and LTOT for patients with chronic hypoxia are the only 
two factors shown to reduce mortality (NIH, 2007). The other interventions central to 
the day-to-day clinical management of COPD involve; addressing the underlying lung 
hyperinflation with bronchodilators and preventing exacerbations with other 
pharmacological (e.g. inhaled glucocorticosteriods) and non-pharmacological care 
(e.g. pulmonary rehabilitation), these interventions significantly influence the overall 
morbidity of the disease (Cooper & Dransfield, 2008).  
Oxygen therapy in COPD 
LTOT is prescribed for arterial hypoxemia in an attempt to prevent or postpone the 
derangements of chronic arterial hypoxemia with regard to end stage organ damage 
(Young, Crockett, & McDonald, 2005). The Ministry of Health (MOH) (2001a) criteria 
for the prescription of LTOT in COPD is an arterial blood gas result taken on room air 
showing a Pa02 of <55mmHg or 60mmHg with evidence of either right heart failure, 
pulmonary hypertension, or polycythemia. This criterion is based on two landmark 
trials; the American Nocturnal Oxygen Therapy Trial (NOTT, 1980) and the British 
Medical Research Council (MRC, 1981) trial. These trials demonstrated that 
domiciliary oxygen for at least 15 hours per day, improved survival of COPD patients 
with chronic hypoxia. LTOT in hypoxemic COPD patients has physiological benefits 
including, reduced pulmonary hypertension, reversal of polycythemia, improved 
exercise performance, increased body weight and improved neuropsychiatric 
functioning (Balter, Danidk, Chapman, Sorba & Rebuck, 1992; MRC, 1981; NOTT, 
1980; Weidzeicha, 2000; Weitzenblum, Oswald, Apprill, Ratomaharo, & Kessler, 
1991).  
 
Over the past 20 years home LTOT has become the major treatment for COPD 
patients with hypoxemia. This in general confers being on oxygen for at least 15 
hours a day for potentially many years. Current oxygen prescriptions within the 
Community Health Service (CHS) where this research was conducted date back as 
far as 1991. The May 2009 CHS oxygen database showed 42% of the LTOT patients 
have been on their treatment for over 5 years. Home LTOT presents both direct and 
indirect impacts on patient and carers; the impacts are both positive and negative. 
Along with cost, quality and equity issues for service providers; it remains for the 
health professionals who prescribe and initiate oxygen therapy to explore the details 
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of the real world of COPD patients on LTOT, so appropriate support and resources 
are targeted and co-ordinated correctly to result in positive outcomes for individuals 
receiving this treatment. 
Adherence to recommended management in COPD 
Oxygen prescription adherence can be variable, older studies have reported that the 
hours those on LTOT use it for are generally fewer than what is prescribed by study 
investigators or physicians (Gorecka, Gorselak, Sliwinski, Tobiasz, & Zielinski, 1997; 
NOTT, 1980). Restrick et al. (1993) interviewed 176 oxygen dependant patients who 
mostly had severe COPD and found that 45% were housebound and many had 
issues with their oxygen, such as social embarrassment, restricted movement and 
discomfort.  
 
A small study of outpatients (n = 48) examining the psychological status of people 
with severe COPD on LTOT (mean age of 57 years) found that most of the study 
participants had depression (79% using the Becks Depression Inventory [BDI]), and 
did not believe in the effectiveness of the long term oxygen therapy (Borak, Sliwinski, 
Piasecki, & Zielinski, 1991). DiMatteo, Lepper and Croghan (2000) conducted a 
meta-analysis of 12 studies about depression and treatment adherence (although not 
in COPD) and found depressed people were three times more likely to be non-
adherent with recommended treatment (odds ratio [OR] of 3.03 95% CI, 1.96-4.89). A 
cross-sectional self administered study of 276 COPD patients (mean age 71 years) 
examining factors associated with non–adherence to medication regimes, revealed 
through multivariate analysis that how a person is feeling and secondly getting 
confused about their medications are important independent predictors of non-
adherence (p values < 0.01) (George, Kong, Thoman, & Stewart, 2005). 
Pulmonary Rehabilitation 
Smoking cessation, optimising function and quality of life with medications and 
pulmonary rehabilitation are principal goals of COPD management. Pulmonary 
rehabilitation involves a spectrum of interventions including patient assessment, 
exercise training, education, nutritional interventions and psychosocial supports. 
These non-pharmacological interventions address the primary and secondary 
impairments associated with chronic obstructive pulmonary disease. Pulmonary 
rehabilitation has become recognised as cornerstone in the holistic management of 
patients with chronic obstructive pulmonary disease (Nici et al., 2006). A Cochrane 
systematic review of 31 randomised control trials (RCTs) by Lacasse, Goldstein, 
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Lasserson and Martin (2006) confirms rehabilitation significantly relieves dyspnoea 
and fatigue, increases exercise capacity, improves emotional function and enhances 
a patient’s sense of control over their condition. In essence pulmonary rehabilitation 
has the ability to break the downward cycle of deconditioning and its associated 
costs shown earlier in Figure 2.1.  
Patient-centred COPD management  
The CHS nursing team consists of specialist and generalist nurses who provide in 
the main, home nursing management for patients with complex often chronic health 
needs including chronic obstructive pulmonary disease. CHS nurses work 
collaboratively with the CHS multidisciplinary team to support the intended patient 
outcomes. The type of respiratory services provided include pulmonary rehabilitation, 
smoking cessation, short and long term home oxygen therapy; home visits for 
support, information about medications, nutrition, dyspnoea management strategies 
and the provision of palliative care. Figure 2.2 shows the make-up of CHS home 
services for respiratory patients.  
 
In day to day practice CHS nurses communicate with the CHS multidisciplinary team, 
general practitioners and the wider primary care practice team reporting, referring 
and transitioning care and clinical information in a timely manner to support effective 
and co-ordinated care. CHS nurses make use of a range of developed assessment 
tools (for example, the Braden pressure risk assessment, Falls risk assessment and 
the Mini Mental State Examination [MMSE] which screens for cognitive impairment), 
to guide appropriate interventions and referrals.  
 
There remain opportunities for improved holistic (physical and psychological) 
assessment and management. Research from the United Kingdom, United States 
and Canada has shown that communication problems are common and that most 
patient complaints are linked with poor communication (Roberts & Bucksey, 2007; 
Simpson et al., 1991). Additionally it has been highlighted in a recent government 
paper: Meeting the Needs of People with Chronic Conditions (National Health 
Committee, 2007), that people in New Zealand want better co-ordination of services, 
clearer information about their conditions and a recognition of their life and culture. 
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Figure 2.2: Community Health Service home services for respiratory related 
conditions 
 
In keeping with contemporary models of patient-centred care, the code of conduct 
and the unique nature of the home care setting, specific care goals should be 
negotiated by patients and families in partnership with the registered nurse. The 
home environment in which the district nurse practices can be favourable to the 
development of a therapeutic relationship. Miller (2002) explored the literature 
examining skills required for effective communication with older people and identified 
that while a person is receiving nursing care in the home it allows a person to have 
greater control of the situation because the nurse is the visitor. Furthermore home 
care can be used to meet societal goals to reduce health care costs such as 
hospitalisation.  
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Patient-centred communication can be described as communication that is 
informative, actively encourages patient participation and questions and responses 
address the physical, social and emotional issues (Seidel, Ball, Dains, & Benedict, 
2006). A literature review by Maquire and Pitceathly (2002) found that patient-centred 
communication resulted in patient problems being identified more accurately. 
Additionally, patients reported more satisfaction with their care, were less distressed, 
less susceptible to depression and anxiety and more likely to adhere to treatment 
and follow behavioural change advice.  
 
However, patient participation within the healthcare setting involves a number of 
complex ethical considerations. Crumbie (2000) considered how ethical principles 
can help to inform decisions about the level of passivity or activity patients should 
have in healthcare. If a nurse utilises the principle of autonomy, then each patient 
has the right to information about their diagnosis and treatment given in an 
appropriate and comprehensible way. Paternalism results in the patient taking a 
passive role in their health care. In relation to beneficence and non-maleficence a 
patient who is actively participating in the process of healthcare needs to be fully 
informed of the consequences of treatment decisions. Finally, justice relates to how 
the just distribution of limited resources and patient participation can be sought 
through consumer advisory groups. These ethical principles dictate that patients 
should be regarded as partners and the nurse has a responsibility to engage patients 
in this way. 
Impact of Depression 
Depression is characterised by alterations in mood, thinking and activity, 
considerable enough to cause impairment in a person and / or social functioning. 
Evidence-based clinical guidelines highlight that depressive disorders are common 
(major depressive disorder rate in NZ estimated at 16%), and under recognised. 
Effective treatments for depression are available and consist of anti-depressants, 
psychosocial and psychotherapeutic interventions. However, resources need to be in 
place in practice to support effective diagnosis, treatment, and follow-up (New 
Zealand Guideline Group [NZGG], 2008; United States Preventive Services Task 
Force [USPSTF], 2002). 
 
Studies show depression in COPD is significant and associated with increased 
hospital admissions, increased length of stay, reduced functional status, poor quality 
of life, poor treatment adherence and premature death (Cully et al., 2006; de Voogd 
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et al., 2009; Fan et al., 2007; Gorecka et al., 1997; Gudmundsson et al., 2005; Kunik 
et al., 2005; Kim et al., 2000; Ng et al., 2008; NOTT, 1980). Kim et al., Kunik et al., 
Lacasse et al. (2001) and Lewis et al. (2007) concluded that there is good evidence 
that depression is often under recognised and undertreated in patients with COPD on 
long term oxygen therapy. Cully et al. comment that because of the impact of 
depression on the lives of people with COPD, working to routinely screen, refer and 
treat depression has the potential to positively affect the quality of care and patients 
quality of life. 
Screening for depression in practice 
Depression assessment measures identify the possibility of depression and provide 
an indication of the severity of symptoms. By recognising depression in this patient 
group, more timely access to appropriate interventions could be achieved and result 
in enhanced quality of care and potentially less impact from depression. Although 
community nurses should gauge depression (MOH, 2001b) as part of routine health 
status monitoring, at the time of this research the nursing service where this research 
was conducted are not using a specific depression screening tool. In the recently 
published National Health Service (NHS) best practice guidance for long term 
conditions (Department of Health, 2009) the percentage of people screened for 
anxiety and depression is listed as a quality indicator of community services. NZ 
does not have such a standard. The United States Preventive Services Task Force 
(2002) clinical guidelines concluded there is insufficient evidence to recommend for 
or against the routine screening with standardised questionnaires for depression in 
primary care. However, targeted screening is recommended by recently developed 
New Zealand guidelines in primary care for “high risk” patients, for example those 
with chronic diseases, chronic pain or social isolation (NZGG, 2008).  
 
Kunik et al. (2008) showed that providing targeted interventions can be effective in 
addressing depression symptoms. Throughout 2002-2005, Kunik and colleagues 
conducted an interventionist RCT involving 238 COPD patients with a mean age of 
66 years and a mean FEV1 of 46% of predicted and who had been treated for 
moderate depression for one year prior to study entry. The groups were split into two, 
120 participants received eight COPD education sessions and 118 received eight 
cognitive behavioural therapy (CBT) sessions. Depression was assessed over the 
follow-up period of 12 months using the BDI-11. The results showed significant 
improvements with both education and CBT (p values <0.005). Mean BDI-11 for 
education group at baseline was 21.12 (standard deviation [SD] 12.09) equal to 
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moderate depression, and at the end of treatment 14.54 (SD 13.47) equal to mild 
depression For the CBT group pre treatment was 23.44 (SD 12.49) and post 
treatment 14.19 (SD 13.69). 
 
Coventry and Hind (2008) completed a systematic review and meta-analysis to 
estimate the effect of pulmonary rehabilitation on anxiety and depression (using the 
BDI-11) in patients with mainly moderate to moderately severe COPD (according to 
FEV1). Three studies involving 269 participants showed that comprehensive 
pulmonary rehabilitation (up to 3 sessions per week involving exercise, education 
and psychosocial support), was appreciably more effective than standard care (out-
patients or primary care, with or without education) in reducing depression 
(standardised mean difference [SMD] = -0.58, 95% CI: -0.93 to -0.23, p=.001). 
 
In end-stage or very severe COPD a person is likely to be mainly housebound, 
breathless at rest and report marked breathlessness with activities of daily living i.e. 
dressing and undressing. Hill, Goldstein and Lacasse (2008) review of anxiety and 
depression in end-stage COPD highlighted that feelings of depression may be 
precipitated by the loss and grief linked with the disability of chronic obstructive 
pulmonary disease. Agusti and Soriano (2008) reviewed depression and other 
additional systemic effects of severe COPD, including weight loss, increased risk of 
cardiovascular disease and osteoporosis. These authors conclude screening and 
appropriate management of these multi-system effects seen in COPD is necessary to 
provide optimal care and improve quality of lives for people with this long term 
condition. 
What the COPD guidelines say about assessing for depression 
Monitoring in COPD can be described as periodically observing, assessing and/or 
testing and recording aspects of a patient’s physical and mental condition. The 
processes regarding the recognition and treatment of depression are given little 
significance in the COPD medical and treatment guidelines (McKenzie et al., 2007; 
NIH, 2007) even though the research indicates depression is a significant issue in 
chronic obstructive pulmonary disease. Van den Bemt et al. (2008) reviewed 18 
clinical practice guidelines which indicate evidence to support the recommendations 
for monitoring patients with COPD are lacking. These authors discuss that it may be 
due to the limited number of well designed trials on this topic. Concluding data should 
be collected on things such as the significance of regular lung function testing and 
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the effectiveness of monitoring dyspnoea and depression; and evaluated for the 
clinical benefits for the patient like reduction in symptoms and improved quality of life.  
 
Summary  
COPD is a multifaceted long-term condition of different pathophysiologies and clinical 
presentations, incorporating pulmonary and extra pulmonary effects. The multi-
system effects generally result in significant impairment and disability for those with 
chronic obstructive pulmonary disease. Ongoing assessment and monitoring, 
supported by effective pharmacological and non-pharmacological interventions are 
needed to optimise the quality of life for people with chronic obstructive pulmonary 
disease. 
 
In practice CHS nurses regularly see patients with COPD on LTOT for assessment, 
clinical intervention, education, support and the provision of equipment at home. A 
nurse will work with the CHS multidisciplinary team and refer to other services and 
providers as appropriate to ensure suitable and timely interventions are provided for 
patients. Currently CHS nurses do not make use of a specific depression screening 
tool. Although depression should be gauged as part of the holistic nursing 
assessment, research has found that depression is often not recognised or treated.  
 
Regular monitoring of the physical and psychological impacts of COPD allows 
clinicians to recognise when a person’s health status declines so they can intervene 
appropriately. With the reported high prevalence and impact of depression in COPD, 
formal assessment for depression may well be useful as part of standard practice to 
improve the quality of the assessment and care provided for depression in this 
patient population. The evaluation of the benefits for the patients of the routine 
assessment of depression is an identified area for future research. The next chapter 
presents the findings of the literature review carried out to position the question and 
inform the design. 
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CHAPTER 3 – LITERATURE REVIEW 
 
This chapter presents a review of the critical points regarding the current knowledge 
of the overall depression prevalence in chronic obstructive pulmonary disease 
(COPD). A survey and critique of the literature regarding depression rates for 
patients with COPD on long term oxygen therapy (LTOT) is provided. The rationale 
for, and design of this study emerged from these research findings and the current 
body of knowledge available on depression prevalence for COPD patients on long 
term oxygen therapy.  
METHOD 
Search strategy 
A literature search and critical appraisal of collected studies were conducted. The 
following abstract databases Pub Med; PsycINFO; Cumulative Index of Nursing and 
Allied Health Literature (CINAHL); and the Cochrane Library were searched. The 
following keywords (MeSH terms) searched were: ‘depression’ and ‘chronic 
obstructive pulmonary disease’ and ‘prevalence’ and ‘oxygen’. Due to the limited 
number of ‘hits’ (n=19) a second search was conducted using the terms ‘depression’ 
and ‘prevalence’ and ‘chronic obstructive pulmonary disease’. English language was 
the only limiter set for the database searches. This latter search yielded 82 articles. 
In addition, studies were identified from the reference lists of the articles yielded. 
Overall 118 abstracts were read that potentially related to this study, from which 27 
studies were appraised. This literature review includes the appraisal of primary 
studies and systematic reviews on the prevalence of depression in chronic 
obstructive pulmonary disease.  
Critical appraisal 
Each of the articles was examined and data were extracted from the full text copy of 
the studies for review. Information obtained and questions for each study included 
the findings, instrument used to diagnose or screen for depression, COPD diagnosis 
criterion, depression instrument diagnosis or risk criterion, recruitment strategy, study 
setting, sample size and profile. Overall, the quality of the primary studies is generally 
good and provides evidence that depression is a common mental disorder in chronic 
obstructive pulmonary disease. All the studies included for appraisal used depression 
measurement instruments that were developed and validated in the English 
language. Overall there was a significant lack of uniformity in methodology and 
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design, resulting in variable prevalence rates. Particularly, different depression 
assessment tools and cut of scores were used to define depression and these affect 
baseline prevalence rates. Other methodological issues such as sampling bias 
(convenience sampling), and limited reporting of some aspects of the clinical and 
demographic profile of the responders and non-responders (e.g. oxygen use, 
ethnicity) limit the validity and generalisability of the results to the New Zealand (NZ) 
practice context. The use of variable COPD diagnostic criteria and disease severity 
inclusions across studies impacts on attempts to compare different studies. 
RESULTS AND DISCUSSION  
Overview of the literature 
The literature review showed the earlier COPD depression prevalence studies were 
generally descriptive (Jones, Baveystock, & Littlejohns, 1989; Light, Merrill, Despars, 
Gordon, & Mutalipassi, 1985), more recently systematic reviews of these prevalence 
studies have been published (Maurer et al., 2008; van Ede, Yzermans & Brouwer 
1999). The primary studies have had similar approaches in collecting data. Generally 
convenience sampling and the use of a range of specific diagnostic or screening 
instruments have been used to measure depression rates in chronic obstructive 
pulmonary disease. Some studies measured the prevalence of anxiety as well as 
depression (Funk, Kitchener, Burghuber, & Hartl, 2009; Lewis et al., 2007). Recently 
population-based approaches have been used to establish the prevalence of 
depression and other co-morbid psychological and physical conditions (Barr et al., 
2009; Scott & Williams, 2007). The studies have been conducted in a number of 
countries. There were no identified studies conducted New Zealand. 
 
Some well published international COPD experts are co-researchers in the more 
recent studies (Barr et al., 2009; Lacasse, et al., 2001). However, there is not one 
prolific COPD researcher who has extensively examined depression prevalence in 
COPD and more specifically in COPD patients on long term oxygen therapy. Overall 
there is a lack of research about depression prevalence for patients with COPD on 
long term oxygen therapy. The literature, although limited, does indicate a high 
prevalence of depression in COPD LTOT patients (Lacasse et al.; Lewis et al., 2007).  
Systematic reviews 
Systematic reviews of the prevalence of depression in older people, people with 
COPD and other disease populations, positions the issue of depression in COPD and 
shows the reported depression prevalence rates vary considerably. A review of 
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depression in older adults (55+) in primary care, reported the prevalence range from 
34 studies (involving over 40,000 participants from different countries) between 0.4-
35% (Beekman, Copeland, & Prince, 1999).  
 
A systematic review specifically investigating the prevalence of depression in COPD 
by van Ede et al. (1999) included 10 studies (860 participants) conducted in the 
1980s and 1990s. van Ede et al. found the prevalence range for depression in people 
with moderate to severe COPD was 7-42%. This systematic review had a 
comprehensive search strategy focusing specifically on depression prevalence in 
people with chronic obstructive pulmonary disease. The studies were reviewed by 
three authors and rated according to five methodological criteria: 1) response rate of 
>80%, 2) control group matched for age and sex, 3) random selection of patients, 4) 
prevalence of depressive disorder detectable and, 5) exclusion of important physical 
disease other than chronic obstructive pulmonary disease. In the review four of the 
studies were case-control studies comparing results between COPD patients and 
controls. All of these case-control studies reported an increased prevalence of 
depression among patients with COPD, but only two of the study’s results were 
statistically significant. The two studies that showed statistically significant 
differences involved 285 patients on LTOT with severe chronic obstructive pulmonary 
disease. 
 
A later review by Solano, Gomes and Higginson (2006) of 64 studies focused on 
depression in advanced acquired immune deficiency syndrome (AIDS), COPD (150 
COPD patients), heart disease, cancer and renal disease, established the prevalence 
of depression in severe COPD ranged from 37-71%. Solano et al. found the high rate 
of depression seen in severe COPD is comparable or greater than that of the other 
advanced disease.  
 
The most recent review (Maurer et al., 2008) was based on a workshop conducted 
by the American College of Chest Physicians, sponsored by the National Institute of 
Mental Health and the Alpha -1 Foundation. The objectives of this workshop were to 
review the current knowledge about anxiety and depression in COPD and identify 
unanswered questions and future research needs. Maurer et al. identified the overall 
prevalence of depression in stable COPD from the results of 16 outpatient studies 
(n=3232) ranges from 10-42%. These authors found that the risk of depression was 
higher (OR 2.5; 95% CI 1.2-5.4) in patients with severe COPD with the highest rates 
(up to 62%) in the oxygen dependant patients.   
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In summary these reviews of studies on the prevalence of depression in people with 
COPD conducted from 1982-2006 have found the presence of depression ranges 
from 7-79%. The latest review (Maurer et al., 2008) included overall large numbers, 
but only one study included LTOT patients (Lacasse et al., 2001). Eleven of the 
studies Maurer et al. reviewed were completed over 10 years ago and five were 
reviewed as part of the van Ede et al. (1999) review.  
Studies that utilised depression screening or diagnostic instruments 
To gain more recent information regarding the incidence of depression in people with 
COPD on LTOT and identify any further research opportunities a critical review of 
identified relevant studies conducted in the past 10 years was undertaken. Table 3.1 
presents the data from these studies.  
 
Concurring with the reviews discussed, the studies detailed in Table 3.1 highlight the 
continued wide range in reported prevalence of depression. Ten of the 11 studies 
show the overall prevalence of depression in people with confirmed COPD (by FEV1) 
ranges from 11-75% using self reported instruments. There are a few main factors 
that contributed to the variation in depression prevalence rates reported. Firstly there 
are factors relating to the methods used to detect people who have depression. 
Some studies used screening questionnaires for example the Hospital Anxiety and 
Depression Scale (HADS) and Becks Depression Inventory (BDI), while others used 
diagnostic interviews for example the Structured Clinical Interview for the Diagnostic 
and Statistical Manual of Mental Disorders, 4th Edition (SCID). Secondly there were 
factors relating to the sample. Studies included patients at different stages of disease 
severity. The studies that included people with more severe disease (as measured by 
FEV1) had higher depression rates. Studies had varying sample sizes and generally 
power calculations were not completed. Some studies had controls while others did 
not. Ethnicity was not always described. Also noted were factors relating to the 
studies setting and methods of data collection. Some studies used self reported 
instruments, some face-to-face interviews, some were postal surveys and some were 
conducted by phone. Where reported the non-response rates ranged from 37% to 
53%. Studies were mainly single centre outpatient. The different methodological 
factors across studies prevent definite conclusions being made about the risk of 
depression and the cross-cultural and geographical variations in depression 
prevalence in chronic obstructive pulmonary disease.  
 
Table 3.1: Primary studies investigating the prevalence of depression in COPD  
Study Setting  Instrument* Sample size  Sample profile Finding / Comment 
Kim et al. (2000)  
 
United States 
Outpatients  
Veterans 
Medical Centre 
Self report: GDS 43 with COPD Mean FEV1 (GOLD) moderate 
Mean age 69 years  
100% male 
86% white 
39.5% had moderate-severe depression 
(GDS>10) 
Small study, all male, mostly white 
47% response rate 
Yohannes, 
Baldwin, & 
Connolly. (2000) 
England 
Outpatients  
Self report: GMS 137 with COPD Mean FEV1 (GOLD) severe 
Mean age 73 
Male 69 female 68 
42% identified as clinically depressed 
Ethnicity not described 
Van Manen et al. 
(2002) 
 
Netherlands 
28 general 
practices  
Self report: CES-D 162 with COPD 
 
359 control 
60 participants had FEV1 <50% 
(European Respiratory Society 
Guidelines)  
Mean age 73  
Male 116  female 46 
Dutch population 
The prevalence of depression was 25.0% 
compared with 17.5% in controls and 19.6% 
in patients with mild to moderate COPD 
(CES-D≥ 16) 
COPD participants had a 2.5 times greater 
risk of depression than the controls 
Kunik et al. (2005) United States 
Outpatients  
Veterans 
Medical Centre 
PRIME-MD, & 
Structured Interview: 
SCID 
1334  FEV1 not defined 
Mean age 65 years 
Over 80% male 
Over 60% white 
80% prevalence of depression using 
(PRIME-MD), 65% using SCID in confirmed 
COPD subset group (FEV1 breakdown not 
provided)  
Wagena, 
Arrindell, 
Wouters, & van 
Schayck. (2005) 
Netherlands 
Inpatients and 
outpatients 
Self report: BDI 118 with COPD 60 participants with severe to very 
severe COPD (GOLD) 
Mean age 57 years, 
55% male 
BDI >15 in 22% of participants with mild to 
moderate COPD compared to 37% for 
those with severe to very severe COPD 
(but p=0.09). 
Ethnicity not described 
Cully et al. (2006) United States 
Outpatients  
Veterans 
Medical Centre 
Self report: BDI –II 179 with COPD Mean FEV1 45.47% (GOLD) 
Mean age 66 years 
95% male 
80% white 
BDI>19 =11%. Mean BDI 22.47 (standard 
deviation[SD] 9.41)  
FEV1 was not associated with BDI-II 
outcomes 
Di Marco et al. 
(2006) 
Italy 
Outpatients 
Self report: SDS, 
Italian version 
202 with COPD. 
114 age 
matched 
controls 
Mean FEV1 54% 
88 participants with severe to very 
severe COPD (GOLD)  
Mean age 61 
Male 155 female 47 
 
 
 
Depression prevalence overall = 19%, 
23.7% for severe COPD, 13.8% for very 
severe COPD (p=0.636). Distribution of 
depression did not reach statistical 
significance. Author comment: LTOT 
excluded as people on LTOT susceptible 
increased psychological impairment 
compared to COPD people on standard 
medical therapy 
Ethnicity not described 
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Table 3.1: continued 
Study Setting  Instrument* Sample size  Sample profile Finding / Comment 
Ng, Niti, Fones, 
Yap, & Tan. 
(2008) 
Singapore 
Outpatients  
Self report: GDS  189 with COPD 
 
2213 without 
Majority had mild COPD 
43.9% having moderate to severe 
COPD (FEV1 <80% GOLD staging) 
55 years and over (37% 55-64 and 
44% were 65-75 years) 
64% COPD population female 
Chinese population 
COPD people depressed =22.8% (12.4% 
for those without COPD) 
GDS>5=depressive symptoms. (OR 1.86 
95%CI 1.25-2.75). Severe COPD = 
increased depressive symptoms. But small 
numbers with FEV1 <50% (only 9.5%). 
Depression was associated with worse 
health & functional status. 
Funk et al. (2009) 
 
 
Austria 
Inpatients and 
Outpatients 
(Vienna primary 
hospital) 
Self report: HADS 122 with COPD 
 
Mean FEV1% (GOLD) 44.5 ± 19.3 
Mean age 65  
Male 68 female 54  
 
Depression=52% (HADS score 8 or 
greater).Depressive symptoms were 
independent of gender (51% of the men; 
52% of the women). FEV1% was lower in 
patients with depressive symptoms (37.0 ± 
15.2) than patients without (52.5 ± 20.0), 
mean difference-15.5, 95% CI-21.8-9.2; 
 p <0.001. 
Ethnicity not described 
 LTOT Studies Setting  Instrument* Sample size  Sample profile Finding / Comment 
Lacasse et al. 
(2001) 
Canada 
Outpatients  
Self report: GDS 
(translated to 
French) 
109 with COPD 
105 on LTOT 
Mean FEV1 34% (GOLD) severe, 
96% on LTOT  
Mean age: 71 
Male 63 female 46 
Average 19 months on LTOT 
 
Total depression rate=75% 
57%; (95% confidence interval [Cl]: 47-66) 
showed significant depressive symptoms 
(GDS≥ 11-19); in addition 18% (Cl: 12-27) 
were severely depressed (GDS ≥ 20) 
Ethnicity not described.  
Consent obtained by usual visiting nurse or 
therapist. Response rate 62% 
Lewis et al. (2007) England 
Outpatients  
Self report: HADS 114 with COPD 
57 on LTOT 
All severe (GOLD) COPD.  
COPD group mean FEV1 34%, age 
67; LTOT group mean FEV1 32%, 
age 70 Male 31 female 26 
Exclusion criteria LTOT<3months 
Average time on LTOT 19 months 
37% of the not on LTOT=depression 
33% on LTOT=depression (HADS ≥ 11) 
p value 0.77 = not significant due to similar 
depression levels between the two groups 
Ethnicity not described. Power calculation 
completed. Postal survey=response rate 
63% 
 *GDS= Geriatric Depression scale. HADS=Hospital anxiety and depression scale. BDI=Beck Depression Inventory BDI-11=second edition. SDS=Self rated depression scale. 
GMS=Geriatric Mental State schedule. CES-D=Centres for Epidemiologic Studies Depression scale. SCID=Structured Clinical Interview for the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition. PRIME-MD=Primary Care Evaluation of Mental Disorders. GOLD= Global Obstructive Lung Disease FEV1% of predicted grading 
criteria.
The Kunik et al. (2005) study had the highest overall depression prevalence of the 
studies in Table 3.1. Eighty percent of the initially phoned screened participants were 
found to have depression. In the subset of COPD patients (confirmed by spirometry) 
65% were diagnosed using SCID with anxiety and/or depression. The authors made 
the comment that the study’s population group are known to have higher prevalence 
of anxiety and depression than the general population. But of note, only 31% of this 
population were receiving treatment for anxiety or depression at the time of the study.  
 
Relevant to practice and this current study there remains a lack of published results 
on the prevalence of depression in COPD patients on long term oxygen therapy. In 
particular lacking is of trials of depression in NZ COPD and/or COPD LTOT 
populations. Only two of the trials described in Table 3.1 included LTOT patients 
(Lacasse et al., 2001; Lewis et al., 2007). These studies do draw attention to the 
potential scale of depression in this COPD population but to date the overall numbers 
of patients described in studies as on LTOT is small and this limits generalisability of 
the research. 
 
The overall reported prevalence could in fact be lower than the number of actual 
cases because of sampling bias (convenience sampling) and under diagnosis. 
Patients with high levels of depression may be less likely to consent to participate in 
studies. Furthermore, one of the challenges in measuring the occurrence of 
depression in COPD patients could be related to the large overlap between the 
symptoms of depression and COPD (van Ede et al., 1999). Both are associated with 
symptoms such as increased fatigue, sleep and appetite disturbances and trouble 
concentrating (APA, 2000; DiMatteo, Lepper, & Crogan, 2000; NIH, 2007). Lacasse 
et al. (2001) reported that by using the GDS they were able to address this overlap of 
symptoms between depression and chronic obstructive pulmonary disease. They 
explained the GDS was specifically developed to be used with well and unwell older 
adults and that it minimises questions about health concerns. A GDS score of ≥ 
11/30 is associated with a sensitivity of 84% and a specificity of 95% for the 
diagnosis of significant depressive symptoms; a score of ≥ 20/30 indicates severe 
depression. 
 
Lacasse et al. (2001) make the point that whether LTOT, in addition to COPD itself, 
contributes to depression is unknown. These authors did not find any clear relation 
between GDS scores and the length of time a person had been on long term oxygen 
therapy. The early landmark LTOT trials (MRC, 1981; NOTT, 1980) were conducted 
before the development of now frequently used disease specific quality of life 
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questionnaires that measure important changes in quality of life and emotional 
function. Since these landmark trials demonstrated survival benefits using low flow 
domiciliary (home) oxygen in hypoxemic patients, LTOT has become the standard of 
care. This creates no further opportunity to randomise hypoxemic patients with 
COPD to receive or not to receive LTOT to measure the effectiveness of oxygen on 
quality of life. 
 
Lewis et al. (2007) found that patients with severe COPD on LTOT do not differ 
significantly in prevalence of symptoms of depression from those with severe COPD 
who are not on long term oxygen therapy. Lewis et al. considered that perhaps by 
relieving breathlessness or improving exercise tolerance, LTOT may lesson 
depressive symptoms. However, this remains unproven and the relationship is 
complex.  
Population based studies 
Scott and Williams (2007) carried out a population study in Canada of mental 
disorder prevalence through face-to-face and phone interviews of 36,984 household 
residents. Scott and Williams utilised the World Mental Health Composite 
International Diagnostic Interview: a fully structured psychiatric diagnostic interview. 
One or more respiratory illnesses were reported by 4,448 of the research 
participants; 1,958 specifically identified they had COPD (chronic bronchitis or 
emphysema). The prevalence of major depression for chronic bronchitis was 8.7% 
(CI 6.8-10.7) and emphysema 7.5% (CI 4.7-10.2) compared to no respiratory 
condition 3.6% (CI 3.3-3.8). Their study relies on self-reported respiratory status, 
rather than a confirmed diagnosis through FEV1 measurement. Scott and Williams 
results show a higher incidence of depression in people with COPD compared to 
people without respiratory conditions. The percentages of depression in COPD are 
quite low compared to other study results that reported on the prevalence of 
depression in people with confirmed (by FEV1) chronic obstructive pulmonary 
disease. These authors concluded that a possible reason for the lower overall 
estimates is because this is a population study and therefore selection bias is 
reduced, signifying selection bias in clinical studies may influence prevalence 
estimations.  
 
A telephone survey in a national sample of 1003 patients with COPD revealed the 
prevalence rate of depression as 37% (p = <0.001). The sample were drawn from 
households where one or more persons were reported as being diagnosed with 
COPD (FEV1 not described). In this survey patients were asked if they had been 
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diagnosed with COPD and then additionally they were asked about a range of 
physician diagnosed co-morbid conditions, depression being one. The published 
report does not outline the specific questions used but state the questions were 
developed by a panel of experts, including physicians, patients and representatives 
from COPD organisations (Barr et al., 2009). This study like the Scott and Williams 
(2007) study was a direct patient survey and a national sample. The key difference is 
that the sample were drawn from a known COPD population. This could indicate 
rather than a study bias, for patients diagnosed with COPD a co-morbid diagnosis of 
depression is common. 
 
SUMMARY 
To date the association between COPD and depression remains unclear as 
depression prevalence is significant across a broad range of populations. The limited 
research on the prevalence of depression in COPD LTOT populations, including NZ 
and the known impact of depression on people with COPD provide the rationale to 
obtain base line NZ information. Depression prevalence rates in COPD are 
statistically and clinically significant. The studies discussed in this chapter although of 
good quality show heterogeneity in the prevalence rates of depression in chronic 
obstructive pulmonary disease. Studies have included various depression screening 
and diagnostic tools, COPD diagnosis criterion, have often not captured important 
variables like disease severity (including whether patients were on LTOT), or 
ethnicity of the study participants.  
 
This literature review highlighted a number of key considerations in the type of and 
way data are collected that informed this point prevalence study to improve the 
applicability, reduce bias and improve potential non-response rates. The COPD 
diagnosis is clearly defined. People on LTOT for conditions other than COPD are 
excluded. The depression criterion also clearly described. People can be described 
by different levels of depression and whether they are being treated for depression at 
the time of the study. The use of a self-reported depression assessment tool that is 
validated for use in the NZ primary care settings was relevant to this study’s setting. 
Selection bias and generalisability is improved by sampling and describing the total 
District Health Board COPD LTOT population (i.e. by age, gender and ethnicity) in a 
large urban area. To improve the response rate in this study, having a methodology 
that made it easy and safe for this population to participate if they would like was 
important. The next chapter focuses on the methodology and study design for this 
prevalence research. 
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CHAPTER 4 – STUDY METHODOLOGY AND DESIGN 
 
An observational point prevalence study was conducted to establish baseline New 
Zealand (NZ) information on the prevalence of depression amongst people with 
chronic obstructive pulmonary disease (COPD) on long term oxygen therapy (LTOT). 
Chapter 4 provides an account of and rationale for the method and materials 
employed for this study. An overview of the aims and objectives is provided, followed 
by an explanation of the background and rationale to the study’s methodology and 
design. The main focus of the chapter relates to the methods of data collection and 
analysis. 
Aims and objectives 
This study’s primary aim was to determine the prevalence of depression amongst 
people with COPD on LTOT in a large urban area in NZ. The objectives were: 
• to describe the characteristics of depressed and non-depressed people (i.e. 
ethnicity, age, gender, disease severity), thereby improving understanding 
about the occurrence and variation of depression prevalence for NZ people 
with COPD on long term oxygen therapy;  
• to inform the introduction of validated depression screening tool as standard 
in practice; 
• to inform future service provision for COPD LTOT patients in the community; 
and 
• to provide new knowledge of the prevalence of depression in the NZ COPD 
LTOT population and add to the total body of knowledge on the prevalence of 
depression in chronic obstructive pulmonary disease. 
Understanding the prevalence of depression in COPD patients on LTOT will highlight 
and potentially enhance health professional’s assessment and interventions for 
individuals with symptoms of depression. At service level, it potentially will positively 
impact the type and level of services provided to this population group.  
 
BACKGROUND TO THE METHODOLOGY AND DESIGN 
Observational research foundations  
Epidemiological health research is concerned with the description of health-related 
states of populations through the collection of data related to the health and 
incidence, distribution and determinants of disease in populations with the aim of 
improving health. Epidemiology research dates back to Hippocrates 400 BC, who 
hypothesised that disease might be associated with the environment. Modern health 
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epidemiology has been led by physicians such as Dr John Snow who is famous for 
investigating the causes of the 19th century cholera epidemic and Doll and Hill (1954) 
who led the British Doctor’s Study that provided strong statistical evidence to support 
the notion that cigarette smoking causes lung cancer. 
 
Epidemiologists make use of observational study designs to examine the frequency 
and distribution of illness. Observational studies have a role in research into the 
patterns of disease and the benefits and harms of medical interventions. This 
information is then often used to investigate causes of disease. Observational 
designs include cohort, case-control, case-report, cross-sectional and ecological 
study designs. High quality observational studies can produce trustworthy evidence 
of intervention effects and can be more clinically relevant than randomised controlled 
trials (RCTs) (i.e. better generalisability or applicability) and include populations of 
interest to clinicians (Lu, 2009). This study used a cross-sectional study design to 
examine the prevalence of depression amongst people with COPD on long term 
oxygen therapy. 
Framework 
The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement details a 22 item check list for cross-sectional study design that 
serves as the now widely used framework to guide what should be included for 
accuracy and comprehensiveness in the reporting of this type of observational 
research (Von Elm et al., 2007). The check list which is freely available on the 
STROBE website (http://www.strobe-statement.org) guided the content of the title, 
abstract, introduction, method, results and discussion for this study.  
Using this framework  
There were five key factors considered as part of ensuring this study’s methods were 
valid and the findings useful locally and elsewhere. Firstly, relating to the overall 
methodology chosen to answer the research question; a cross-sectional design was 
used as it is the best way to determine prevalence of a health problem. A cross-
sectional study aims to describe the connection between disease and other factors of 
interest as they exist in a particular population at a point or period in time and may be 
used as a basis for health policy decisions (Mann, 2003). Although this type of study 
identifies the existence of health problems at a point in time it does not identify 
cause-and-effect relationships. Prevalence is significant to the clinician because it 
influences the likelihood of a certain diagnosis and the predictive value of an 
investigation. In prevalence studies the participants are assessed at one point in time 
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to establish whether they were exposed to an intervention or risk factor and whether 
they have an outcome (Lu, 2009). 
 
Secondly, the generalisability and external validity of the data in the NZ and wider 
health context were considered. This prevalence study sampled the total COPD 
LTOT population in a large urban region of NZ. Describing the population 
characteristics will enable those appraising this research to assess its applicability to 
their population of interest. The generalisability and external validity of the results is 
high amongst this population group in NZ, but as it is a narrowly defined population 
the generalisability is limited outside COPD LTOT population. 
 
Addressing the possible reasons for non-response can improve a study’s validity. If 
the reasons for non-response are not related to the health outcome measured and 
the characteristics of the non-responders are comparable to the responders, 
researchers are better placed to justify a modest response rate. However, response 
rates can be improved if the assessment is easily accessible (i.e. home might be 
more suitable for the elderly), conveniently timed, acceptable in length and 
appropriate in content for participants (Loney, Chalmers, Bennett, Roberts, & 
Strafford, 2000). 
 
Thirdly, it is important to know what sample size is required to ensure the study is 
sufficiently powered to be statistically and clinically significant. Generally the higher 
the number of selected participants who are not available for measurement, the less 
valid the estimate is (Peat & Barton, 2005). To be sufficiently powered the response 
rate for this study was estimated at 61. This calculation was undertaken using a 
computer program (http://sampsize.sourceforge.net/iface/index.html). The sample 
size calculation assumed a precision of 5% and depression prevalence of 33% taken 
from the results of the study by Lewis et al. (2007) and this study’s total population 
(n=73) size. The study was not powered to consider differences between subgroups.  
 
The fourth point considered was addressing the potential sources of bias in this 
study. The self-administered depression questionnaire was left with some of the 
participants to complete so others could have filled it in on their behalf. Additionally, 
using a depression questionnaire that is freely available access (i.e. on-line) 
potentially allowed people to alter their scores to try and reflect a more favourable 
response. These issues were addressed to some degree by statements in the 
consent form (Appendix 2) and information sheet (Appendix 3) such as “The Patient 
Health Questionnaire-9 (PHQ-9) is a screening questionnaire only and positive 
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results would not necessarily mean you have depression” and “I agree to my 
depression questionnaire results being sent to my GP YES/NO”. Participant study 
information, support and follow-up offered were provided to fully inform and ease any 
concerns a person may have regarding their depression questionnaire results. 
However, those people that chose not to participate may have done so because of 
depression or because they did not want to be screened for depression.  
 
The final key factor was to consider the measurement tools used to answer the study 
question. The literature review reflected a range of screening tools in existence that 
could be appropriately used to assess depressed mood in people with COPD. For 
example the Becks Depression Inventory (BDI) used in a few of the presented 
studies in Chapters 2 and 3 was originally developed in 1961, revised in 1978 and 
again in 1996 (BDI-11). The BDI is one of the most frequently used and well 
validated measures of the severity of depression in adolescents and adults by both 
researchers and clinicians, it has been validated in a range of countries, settings, 
languages and ethnic groups (Grothe et al., 2005). Also the Geriatric Depression 
Scale (GDS) has been shown to have good sensitivity (correctly identified as 
condition positive by a positive result) and specificity (correctly identified as condition 
free by a negative result) in older adults (Lacasse et al., 2001). As there were no 
identified NZ studies conducted using these measurement tools evidence-based 
guidance for this study was sought from the recently published NZGG publication: 
Identification of Common Mental Disorders and Management of Depression in 
Primary Care (2008) for the best tool for NZ community nurses to use for research 
and practice. 
 
The short either clinician or self-administered PHQ-9 is identified in the NZGG (2008) 
publication as being valid and reliable in adults for identifying and assessing the 
severity of depression in primary care. A primary care screening tool was considered 
to be the best tool as community nurses provide preventative and ongoing essential 
home care, working to co-ordinate and support the transition of people’s overall care 
back to the primary care practice (a person’s medical home).  
 
The PHQ-9 was developed by Spitzer and colleagues and scores the nine symptoms 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (APA, 2000) of 
major depression criteria as “0” (not at all) to “3” (nearly every day) giving a score 
range of 0-27. The recommended cut of scores for the PHQ-9 are 0-4 (none), 5-9 
(mild), 10-14 (moderate), 15-19 (moderately severe), 20-27 (severe). Although there 
is limited data about the PHQ-9 use with COPD patients, there is a range of good 
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information about the assessment of depression, and use of this tool in other chronic 
illnesses in primary care (Maurer et al., 2008; NZGG, 2008).  
 
Two recent studies examined the validity of the Patient Health Questionnaire-9. The 
PHQ-9 was compared to the BDI-11 by Dum, Pickre, Sobell and Sobell (2007) in 108 
outpatient’s substance abusers. Dum et al. found both tools to have good internal 
consistency (Cronbach’s alpha reliability coefficient of the BDI-11 and the PHQ-9 
were 0.95 and 0.91 respectively). Dum et al. studied substance abusers so the 
results cannot be directly extrapolated to COPD patients. More recently the validity 
and reliability of the PHQ-9 were examined in a population of elderly Dutch patients 
(n = 713) from 89 general practices diagnosed with diabetes and COPD without 
known depression (Lamers et al., 2008). Lamers et al. found that when the PHQ-9 is 
used as a continuous measure (representing depression severity ranges from 0-27), 
summing the responses to the nine questions (rather than using the scoring 
algorithm with a cut off point for major depressive disorder and any depressive 
disorder), the PHQ-9 was valid and reliable in elderly COPD and diabetic patients. 
The test-retest internal reliability (Cronbach’s alpha) for the PHQ-9 in the COPD 
participants was 0.84 (n = 79). A test-retest of the summed score (Pearson’s r 
intraclass correlations coefficient [ICC]) were also conducted in these 79 patients and 
was 0.90. The optimal cut of point was PHQ-9 ≥6 for any depressive disorder with a 
sensitivity of 95.6% and a specificity of 81.0%. Additionally, the PHQ-9 tool is simple 
to use taking generally less than five minutes to complete and is free for researchers, 
clinicians and the public to access. This current study used a score of 5 or more as 
an indication of depression. 
ETHICS 
 
The Central Regional Ethics Committee approved this study via the national ethics 
application process in July 2009 (Appendix 1). There were two key ethical 
considerations identified in the development of this study to address participant 
safety given the nature of this research. Firstly, minimisation of harm; all registered 
nurses assisting with this study were bound by confidentiality, professional standards 
and scopes of practice. They were provided with specific training by the lead 
researcher (supported by research supervisor) about the information and consent 
process and about the self reported depression and demographic questionnaires. 
The nurses were advised that where a patient’s depression questionnaire (PHQ-9) 
results indicated depression they would inform the patient about the results and 
develop a plan in partnership with the patient, including advising the person to see 
their general practitioner (GP). The GP was only informed of the PHQ-9 results with 
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the patients consent (Appendix 4). The participant consent form and information 
sheet (Appendix 2 and 3) cover the participant information regarding this issue.  
 
Secondly, Treaty of Waitangi obligations; the study aimed to incorporate Māori (the 
indigenous people of NZ) to generate useful data without imposing an unethical 
burden on Māori. Hospital clinical records showed Māori were over 20% of the COPD 
LTOT population at the time of the study. Consultation with Māori resulted in support 
being offered to Māori participants by Whanau Care Services registered nurses 
whose role is to provide advocacy and support to Māori Whanau (family) and 
providers working with Māori (Appendix 5). 
THE METHODS 
Study population 
In September 2009 the cross-sectional study among the total population (n=73) of 
COPD patients on LTOT registered to the District Health Board (DHB) Community 
Health Service (CHS) was conducted. Although ethics approval was granted in July 
2009, data collection was delayed until September so the impact of winter colds and 
flu (significantly the impact of the 2009 swine flu outbreak) did not limit patient 
participation or place an increased burden on the community nursing staff coping 
with high winter workloads and staff illness. 
 
The participants were outpatients with a clinical diagnosis of COPD (generally 
confirmed by an FEV1 ≤ 80% as per the Global Obstructive Lung Disease (GOLD) 
guidelines (NIH, 2007), who had been on LTOT for more than three months. The 
researcher set the participant criteria of being on LTOT for at least three months to 
allow time for people to adjust to a new treatment (LTOT). This timeframe was in line 
with the Lewis et al. (2007) study that examined depression in a similar patient 
population. Recruitment for this study involved four phases: 
1. Identification of COPD patients on LTOT prior to June 2009.  
2. Collection of baseline data from hospital records on all patients who meet the 
inclusion criteria. These data extracted on all patients were used to determine 
the representativeness of the responders. 
3. All patients who meet the inclusion criteria were initially phoned by the 
principle researcher (generally known to the patients) to ask if they consented 
to a home visit (usual care setting for this CHS patient group) by their primary 
CHS nurse or the nurse researcher to receive information about participating 
in the study. 
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4. The CHS primary nurse or the nurse researcher visited the patients who had 
agreed to a visit to deliver the information, consent forms and questionnaires 
for completion. 
Data collection and measurement instruments 
Base-line demographic (age and gender) and clinical information (COPD diagnosis, 
COPD admissions and oxygen prescription details) were obtained from hospital 
records on the DHB COPD LTOT population. The participants were given two short 
questionnaires for completion, the questionnaire developed for this study (Appendix 
6) and the Patient Health Questionaire-9. The nine questions of the validated PHQ 
are listed in Appendix 7. The developed questionnaire contained additional 
demographic questions about ethnicity, employment and whether they lived alone or 
not and clinical information about COPD treatment (LTOT usage, portable oxygen 
and pulmonary rehabilitation) and any depression history and treatment. Tables 4.1 
and 4.2 lists all the demographic and clinical variables collected from the hospital 
records and the questionnaire developed for this study.  
 
Table 4.1: Demographic variables by name, description, values and type 
Variable name Variable description Values Variable type 
Age Age at recruitment In years Continuous 
Ethnicity Ethnic status NZ European 
Māori 
Pacific 
Asian 
Other * 
Nominal 
Gender Gender Female 
Male 
Nominal 
Employment  Employment status at 
recruitment 
As per description* 
 
String 
Living situation Lives alone Yes 
No 
Nominal 
*asked to describe 
 
A number of factors guided the data collected for this study. The Treaty of Waitangi 
guides the inclusion of ethnic status. This research aims to incorporate Māori 
participants to provide relevant information for practice. Capturing the details (i.e. 
age, gender, FEV1 and LTOT prescriptions) of the non-responders and responders 
provides an overview of the population studied that other people examining or using 
the research can relate to and consider its relevance to different populations. 
 
The participants were asked whether they were currently being treated for 
depression but were not asked to expand on the type of treatment they were 
receiving. The researcher did not consider the inclusion of additional questions about 
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the type of depression treatment a person was receiving added value to the aims of 
this study. For the participants, asking extra questions about medications and 
counselling may have been more inconvenient in terms of time to taken to complete 
the questionnaires and may have been perceived as more personally invasive. 
 
Table 4.2: Clinical variables by name, description, values and type 
Variable name Variable description Values Variable type 
FEV1 Last recorded FEV1 % of predicted Continuous 
LTOT prescription Actual hours prescribed oxygen  In hours Continuous 
MonthsO2 Length of time on oxygen In months Continuous 
LTOT usage Actual hours uses oxygen per day In hours Continuous 
Portable oxygen use Portable oxygen Yes 
No 
Nominal 
Pulmonary Rehabilitation If completed Yes 
No 
Nominal  
Pulmonary Rehabilitation Time since completion Time in 
months 
Continuous 
Hospital admissions  Number in previous 12 months Number Continuous 
 
Length of stay Total length of stay in days in 12 
months 
Number Continuous 
History of depression Told by a health professional Yes 
No 
Nominal 
Depression treatment Current treatment Yes 
No 
Nominal 
 
The literature and policy reviewed as background to this study also influenced the 
type of data collected. For example smoking status was not included, as it is a 
contraindication for the prescription of LTOT in NZ (MOH, 2001a) and it was 
considered that inclusion of the information may be perceived negatively by 
participants. Living alone and employment status were asked about as these socio-
demographic variables have been associated with depression (Lewis et al. 2007). 
The decisions to use the PHQ-9 and extend the data collected to include hours of 
oxygen usage, hospital admissions, pulmonary rehabilitation, ethnicity and availability 
of portable oxygen; over and above the only two similar studies published at the time 
of this study (Lacasse et al., 2001; Lewis et al., 2007) described in Chapter 3, were 
made to provide more meaningful information for local practice. 
Procedure 
A pre-test was conducted involving two people to determine the ease and suitability 
of the developed questionnaire and the Patient Health Questionaire-9. As no 
changes were required and the two people involved had fully consented their data 
were included in the study. 
 
 - 31 -
Both questionnaires were completed by the study participants in their homes, either 
at the time of delivery or at their own convenience. The completed questionnaires 
were either collected by the CHS primary nurse or returned by the participant within 
two weeks by post (stamped envelope provided) to the researcher for scoring and 
analysis. 
Data Analysis 
Data analysis was guided by Peat and Barton (2005). The Statistical Program for the 
Social Sciences (SPSS) version 16 programme was used for all statistical analyses. 
Tests for normality were applied. The information collected was put into an Excel 
spread sheet, cleaned and exported to SPSS. A five step analysis plan was 
undertaken. The coding sheet for the data analysis is given as Appendix 8. 
 
Step one involved describing the total COPD population demographically and 
clinically, using descriptive statistics of measures of central tendency (mean, median, 
mode and frequency) and measures of dispersion (standard deviation, inter-quartile 
range and range). 
 
Step two involved describing the additional clinical (i.e. oxygen use, pulmonary 
rehabilitation) characteristics of the respondents using similar statistics to step one. 
 
Step three compared the baseline characteristics of the respondents and the non-
responders using inferential statistics such as chi square, and Fisher exact test for 
nominal variables, and t-test or Mann-Whitney U-test for continuous variables 
depending on the distribution of data. 
 
Step four determined the prevalence of depression. The prevalence of depression 
was defined as the population of depressed patients (PHQ-9 score of 5 or more) 
identified among the total of patients surveyed (95% confidence intervals [CI]). 
 
Step five determined differences and relationships between depressed and not 
depressed participants, using inferential statistics such as Spearman’s correlations 
and Mann-Whitney U-test.  
 
In summary the research was designed and carried out in all stages to generate 
rigorous and valid results. Particular care was taken to ensure the process was safe 
for people. The following chapter presents the findings.  
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CHAPTER 5 – RESULTS 
 
This chapter presents the findings. It commences with a description of the 
demographic and clinical characteristics of the population of patients with chronic 
obstructive pulmonary disease (COPD) on long term oxygen therapy (LTOT) for a 
minimum of three months under the care of Capital Coast District Health Board (C&C 
DHB), as at September 2009. The findings of the point prevalence study of 
depression in the sampled population are then presented. In these analyses, 
statistical significance was set at p value ≤ 0.05. 
 
Study population 
The total population of 73 people with COPD on LTOT were contacted for verbal 
consent to receive the information and questionnaires needed to participate in the 
study. Three people were excluded due to acute illness and being in hospital during 
the data collection period, five declined to participate and two did not return their 
questionnaires. For the present study, baseline data from the total population of 73 
were used to compare the characteristics of the responders (n=63, 86%) and all 
those who did not complete the questionnaires (referred to as non responders) 
(n=10, 14%).  
PATIENT CHARACTERISTICS 
Overall descriptions 
The baseline demographic and clinical characteristics collected from hospital records 
(age, gender, FEV1, oxygen [o2] prescription [Rx] in hours per day and date of 
commencement) of the total population are shown in Table 5.1. There were no 
statistically significant differences in the baseline characteristics for the responders 
and non-responders. The independent t-tests for the continuous variables show the 
means on all the variables of the two groups were similar. The Fisher exact results 
confirm the frequencies of the conditions are not significantly different between the 
two groups.  
 
The baseline results show this COPD LTOT population are mainly an older female 
population. The number of people living in rest homes (n=4) was too small for a 
separate analysis. Ten percent of the population were 60 years or younger. Most 
people had been on LTOT for over two years with one person being on LTOT for 
nearly 19 years. The FEV1 results indicate that people had mainly very severe 
COPD (FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory 
failure). There were four people whose last recorded spirometry showed only mild 
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COPD (FEV1 80%) and no hospital spirometry records were located for eight people. 
Each of the eight people had a documented physician diagnosis of COPD recorded 
in clinic letters, oxygen prescriptions and/or discharge summaries. Six of the eight 
had been on LTOT for one to three years and two people had been on LTOT for 10 
years. 
 
Table 5.1: Demographic and clinical characteristics of the responders and non-
responders 
Characteristic Values Returned 
n = 63 (100%) 
Not returned/ 
declined 
n = 10 (100%) 
Significance 
Gender Male 
Female 
27(43%)
36(57%)
2(20%)
8(80%)
Fisher’s exact p = 0.297
Age Mean(SD) 
Range 
72(8.7)
54-89
72(7.0)
59-79
t = 0.016, df = 71, p = 0.987
FEV1% Valid 
Missing 
Mean (SD) 
Range 
55(87%)
8(13%)
37(17)
             13-80 
8(80%)
2(20%)
41(16)
29-80
t = -0.599, df = 61, p= 0.551
o2 Rx 16/16+ hours 
24 hours 
PRN 
Nocturnal 
46(73%)
10(16%)
5(8%)
2(3%)
7(70%)
3(30%)
Fisher’s exact p = 0.607
Months on o2 Mean (SD) 
Range 
48(47)
4-216
43(39)
3-132
t = 0.287, df = 71, p = 0.775 
Hospital 
admission 
Yes 
No 
37(59%)
26(41%)
6(60%)
4(40%)
      Fisher’s exact p = 1.000 
 
Over half of the total population had had an inpatient hospital stay in the previous 12 
months. Twenty people (27%) having had one admission and 23 (31%) had between 
two and five admissions. These admissions had resulted in a total length of stay 
(LOS) of ≥10 days for 17 people (39%) and a LOS of over 20 days for six people 
(14%).The results shown in Table 5.1 confirm that 89% (n=56) of prescriptions are for 
oxygen to be used between 16-24 hours per day.  
 
Responder’s additional descriptions 
The additional demographic and clinical (relating to COPD management) 
characteristics collected from the 63 respondents are shown in Table 5.2. Given the 
mean age (72 years) of the population, the high number of retired people shown in 
Table 5.2 was not unexpected. Māori only and Māori plus European represent 22% 
(n=14) of the responders and nearly 10% (n=6) of the responders identified 
themselves as being of Pacific Island ethnicity. The results indicate that 43% (n=27) 
of responders had either not attended pulmonary rehabilitation or didn’t know 
whether they had attended. The majority of people who had attended pulmonary 
rehabilitation had done so 12 or more months ago. Over 70% (n=46) indicated they 
did not have portable oxygen to use outside the house. Several of this study’s 
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participants put additional comments on their questionnaire, saying they would like 
portable oxygen. Seven people on LTOT (generally prescribed for 15+ hours) were 
prescribed either nocturnal or PRN oxygen and six of these people were using their 
oxygen fewer than 15 hours per day. Additionally, 32% (n=18) of the responders 
prescribed LTOT for 16-24 hours per day reported using it for fewer than 15 hours 
per day.  
 
Table 5.2: Demographic and clinical (COPD management) features of 
responders  
Characteristic Values Returned 
n = 63 (100%) 
Ethnicity Māori 
European 
Pacific 
Asian 
Other 
Māori and European 
11(17.5%)
40(63.5%)
6(9.5%)
1(1.6%)
2(3.2%)
3(4.8%)
Employment Retired  
Paid work 
Unemployment 
Other benefit 
Self employed 
52(83%)
2(3%)
4(6%)
4(6%)
1(2%)
Lives alone Yes 
No 
Missing data 
18(29%)
44(70%)
1(1%)
o2 usage in hours <5 
5-9 
10-14 
15-19 
20 or more 
4(6%)
5(8%)
17(27%)
17(27%)
20(32%)
Portable o2 Yes 
No 
17(27%)
46(73%)
Pulmonary Rehab Yes 
No 
Don’t know 
36(57%)
17(27%)
10(16%)
 
DEPRESSION SCORES 
In Figure 5.1 the histogram has the tail to the right showing fewer people had higher 
depression scores at the upper end of the distribution. The distribution of this variable 
guided the use of non-parametric statistical tests to compare means across the other 
variables in relation to the depression scores. 
 
Of the 14 who reported a history of depression all but one (who was currently on 
treatment for depression) had a PHQ-9 score of 5 or more. In total, nine of the 14 
respondents were being treated for depression. One of the responders, who did not 
report a history of depression, reported they were on current treatment for 
depression; their PHQ-9 score was zero.  
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Figure 5.1: Histogram of distribution of the PHQ-9 scores 
 
The results of the depression questions are presented in Table 5.3. The prevalence 
of depression was defined as the percentage of depressed patients among the total 
number of patients that were surveyed. The overall point prevalence of depression as 
measured using the self reported patient health questionnaire-9 (PHQ-9) when a 
score was 5 or more was 54% (n=34) (95% CI 41.71 - 65.87). The depression scores 
for 29% (n=18) of people indicated moderate to severe depression (score 10-27). 
Although over half of the respondents’ PHQ-9 scores indicated depression, fewer 
than a third reported a history of depression.  
 
Table 5.3: PHQ-9 scores and depression history of the responders 
Characteristic Values Returned 
n = 63 (100%) 
PHQ 9 total score Mean (SD) 
Median 
Range 
7(7)
6
0-27
PHQ-9 scale 
(95% CI) 
None (0-4) 
Mild (5-9) 
Moderate (10-14) 
Moderately severe (15-19) 
Severe (20-27) 
              29(46%)  CI 34.13 – 58.29 
16(25%) CI 15.92 – 37.08
7(11%) CI 5.11 – 20.58
5(8%) CI 3.09 – 16.52
6(10%) CI 4.07 – 18.58
History of 
depression 
Yes 
No 
Missing data 
14(22%)
48(76%)
1(2%)
Current treatment 
for depression 
Yes 
No 
10(16%)
53(84%)
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Table 5.4 shows that two of the six people reporting symptoms of severe depression 
were not being treated for depression. Nine of the 12 people with moderate to 
moderately severe depression were not being treated for depression. 
 
       Table 5.4: PHQ-9 severity scores and depression treatment  
PHQ-9 severity Depression 
Rx Yes 
Depression Rx 
No 
Total 
None 1 28 29 
Mild 2 14 16 
Moderate 1 6 7 
Moderately severe 2 3 5 
Severe 4 2 6 
Total 10 53 63 
 
Forty (63%) responders consented to their general practitioner (GP) being informed 
of their PHQ-9 results.  
 
Predictors of depression 
Table 5.5 highlights there were no significant correlations between the PHQ-9 total 
scores and a person’s age, FEV1, number of hospital admissions and length of time 
a person has been on long term oxygen therapy. Spearman’s correlations were used 
as the data was treated as non-parametric. 
 
Table 5.5: Correlations between the PHQ-9 total scores and demographic and 
clinical characteristics 
PHQ-9 total Spearman’s 
correlation 
Sig.(2-tailed) 
Age .036 0.77
FEV1 .139 0.31
Months on oxygen .151 0.24
 
There were also no statistically significant differences on the subgroup analyses of 
the demographic and clinical variables (Table 5.6). Non-parametric statistics were 
used because of the data distribution of the PHQ-9 scores. However, there was a 
near significant result for the living alone variable. Those who lived alone had higher 
PHQ-9 scores indicating the likelihood of more serious depression than those living 
with others. The box plot shown in Figure 5.2 presents the distribution of the PHQ-9 
scores by gender. Female respondents reported more moderate to severe 
depression scores.  
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 Table 5.6: Demographic and clinical factors that impact on depression 
 
Characteristic Values No Median (IQR) Mann Whitney U 
Gender Male    
Female 
27
36
7 (2-10)
5.5 (2.0-14.5)
z = -0.237, p = 0.813
Lives Alone Yes    
No      
18
44
9.5 (2-19)
4.5 (2-8)
z = -0.364, p = 0.088
Portable o2 Yes    
No    
17
46
7 (2.0-14.5)
6 (1.75-10.25)
z = -0.738, p = 0.460
Using less o2 than Rx Yes   
No     
40
23
5.5 (2-10.75)
7 (2-13)
z = -0.172, p = 0.864
Completed pulmonary rehab Yes  
No    
36
17
3.5 (2.0-7.75)
7 (0.5-11.5)
z = -0.364, p = 0.716
Hospital admission Yes   
No     
37
26
4 (1-10)
7 (3.0-12.25)
z = -1.78, p = 0.750
 
 
 
Figure 5.2: Box and whisker plot of mean PHQ-9 total scores by gender* 
*Mean (bar), upper and lower quartiles (edges of box), and 95% data coverage (end of whiskers) 
 
 
SUMMARY 
This cross-sectional prevalence study has reported on the incidence of depression 
amongst a total DHB population of people with COPD on long term oxygen therapy. 
The clinical, service and research implications of these findings and their relevance 
to nursing practice are discussed in the next chapter. 
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CHAPTER 6 – DISCUSSION AND CONCLUSION 
 
The focus of this observational research was to ascertain the prevalence of 
depression amongst people with chronic obstructive pulmonary disease (COPD) on 
long term oxygen therapy (LTOT) in a large urban region in New Zealand (NZ). The 
study’s objectives were to 1) describe the characteristics of depressed and not 
depressed people with COPD on long term oxygen therapy 2) inform the introduction 
of a validated depression screening tool as standard in practice 3) add to the total 
body of knowledge about depression in this patient population and provide new 
information about the prevalence of depression in a NZ COPD LTOT population, and 
3) inform future service provision for COPD LTOT patients in the community setting. 
 
Following a comprehensive literature search (Chapter 3) it became evident that there 
was limited research about the prevalence of depression in LTOT COPD populations. 
There are a number of studies about depression prevalence in general COPD 
populations, but there is significant heterogeneity in the published studies design and 
methodology. In this chapter the design, methods and findings of this point 
prevalence study will be discussed and compared in relation to the two most recent 
identified published studies, (Lacasse et al., 2001; Lewis et al., 2007) that examined 
depression prevalence in COPD LTOT populations. The limitations of this research, 
future research and practice recommendations that emerged through this study will 
also be presented  
 
The main findings 
A quarter of patients in this study reported mild symptoms and nearly a third had 
moderate to severe symptoms of depression using the Patient Health Questionnaire-
9 (PHQ-9). Although almost one in three people surveyed reported significant 
depression symptoms, only one in six people reported they were currently being 
treated for depression (see table 5.4). The study participants were not asked to 
specify what that treatment was. This is new knowledge regarding the important 
issue of depression amongst people with COPD on LTOT in New Zealand. It adds 
weight to the total body of knowledge regarding the high prevalence of depression in 
COPD LTOT populations. 
 
Demographic and clinical profiles 
Overall this study reported demographic and clinical information was similar to 
Lacasse et al. (2001) and Lewis et al. (2007). The age, gender, diagnosis of COPD 
using the GOLD (NIH) criteria, whether a person lived alone, length of time on 
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oxygen, type of oxygen delivery systems (stationery and portable) and whether a 
person was currently being treated for depression were reported. Both Lacasse et al. 
and Lewis et al. asked about co-morbidities. Lacasse et al. asked about education 
and Lewis et al. asked whether the person was housebound and had had any major 
or upsetting life events e.g. hospital admission or bereavement in the past six 
months. This study sought hospital admission and length of stay data for the 
population from hospital records. 
 
Lewis et al. (2007) had also asked about current smoking status, this study did not 
seek to collect that information given that smoking is contraindicated in the NZ 
oxygen provision specifications (MOH, 2001a). It was felt that inclusion of this 
question could limit participation and also those currently smoking might not 
accurately report this. Lewis et al. study examined the prevalence of anxiety as well 
as depression and compared LTOT and non-LTOT patients with chronic obstructive 
pulmonary disease. Lacasse et al. (2001) examined the relationship between 
depression scores and a validated medical (not chronic respiratory specific) quality of 
life questionnaire. This study focused additional reporting on ethnicity, the oxygen 
prescription in hours per day and the actual hours a person used their oxygen for and 
whether they had attended pulmonary rehabilitation. These additional items captured 
important information to this study’s context about the number of Māori on LTOT, 
prescription adherence, and hoped to identify any impact on mood pulmonary 
rehabilitation has. 
 
Data collection 
Previous literature reviews (Maurer et al., 2008; van Ede et al., 1999) have 
highlighted the heterogeneity of studies examining the prevalence of depression in 
COPD. van Ede et al. recommended that studies needed to include good 
methodological design, use a validated depression measure for COPD patients and 
be adequately powered. This study addressed all three recommendations. It was well 
designed, used an instrument validated for use in New Zealand and the study was 
adequately powered. In addition because of the high response rate (86%), response 
bias was minimised. The response rate in this study was significantly higher than the 
response rates for both Lacasse et al. (2001) and Lewis et al. (2007) which reached 
just over 60%, suggesting this study had an effective data collection process for a 
study of this type. Given the high response rate and the fact that this study sampled 
the total District Health Board (DHB) COPD LTOT population, the responders and 
non-responders clinical and demographical characteristics collected are highly 
representative. 
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This study employed a data collection tool and approach that was widely used, 
simple, acceptable and relatively quick to complete for those participating. Lacasse et 
al. (2001) and Lewis et al. (2007) both discussed that ease of completion was a 
factor in their choice of depression measurement tool. This study utilised the PHQ-9 
depression assessment tool. The PHQ-9 can be self-completed and has been 
validated and recommended for use in NZ, primary care and COPD. As this was the 
first prevalence study in this population in NZ the use of this measurement tool was 
appropriate to this study’s context. Lacasse et al. used the Geriatric Depression 
Scale (GDS) in an attempt to improve the estimation of depression in the generally 
older COPD LTOT population. They concluded that many depression questionnaires 
include items that may be part of the aging process, such as early morning waking 
and reduced libido and the inclusion of such items could over estimate the 
depression prevalence in this population. These items are not included in the PHQ-9. 
Lewis et al. had used the Hospital Anxiety and Depression Scale (HADS) a tool 
developed originally for hospital use that measures anxiety also. 
 
The variables collected and the statistical analysis sought to establish the overall 
prevalence of depression with the secondary aim to inform potential service and 
practice improvements for the COPD LTOT population. Defining the characteristics of 
the total population, establishing the prevalence of depression amongst the 
responders and examining the distribution of their depression scores was done to 
achieve the primary aim. Examining the differences and correlations when the 
depression score is the dependant variable and demographic and clinical variables 
are introduced to see whether a significant change is produced, was completed to 
add valuable insights for practice.  
 
The findings compared  
The overall depression prevalence rates were not dissimilar in this study (with mild 
cases 25% and moderate to severe depression 29%) compared to Lewis et al. 
(2007) (with borderline cases 35% and definite cases of depression 26%). Lacasse 
et al. (2001) found higher rates of depression in their study population (57% 
significant symptoms and 18% severely depressed). It is difficult to draw any 
conclusions about the specific numbers as different measurement tools were used. 
However, this study’s results are in line with these previous similar studies 
highlighting the importance of mood disturbance in this population.  
 
Depression in COPD is important, as well as personal morbidity (Cully et al., 2006) it 
has been associated with increased utilisation of healthcare resources and early 
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death (de Voogd, 2009; Gorecka et al., 1997; Gudmundsson et al., 2005; Ramset et 
al., 2007). Whether LTOT, in addition to COPD alone, contributes to depression is 
unknown. Lewis et al. (2007) results suggested that patients with severe COPD on 
LTOT have similar prevalence of symptoms of anxiety and depression (using the 
Hospital Anxiety and Depression Scale) to those with severe COPD who do not meet 
the criteria for long term oxygen therapy. 
 
This current study found that 32% of people were using their oxygen for fewer than 
15 hours a day, even though the prescription and advice is to use their oxygen for 15 
hours or more every day. Depression has been associated with poor treatment 
adherence (Cully et al.; 2006; DiMatteo et al.; 2000). However, there were no 
differences in the mean depression scores for those using their using their LTOT for 
16-24 hours compared to those who were using it less than 15 hours. Additionally the 
results did not show any clear relation between depression scores and the length of 
time a person had been on long term oxygen therapy. Nor were there any differences 
in mean depression scores for those with portable oxygen. This study’s results like 
Lewis et al. (2007) suggest that LTOT does not have an impact on depression 
symptoms. The lack of positive impact from LTOT on the PHQ-9 scores could relate 
to the fact that LTOT is generally prescribed late in the disease continuum where, 
very often a person is substantially limited functionally and so they may not be able 
make meaningful physical and emotional gains with the introduction of oxygen. 
 
This study also examined the differences and correlations in depression scores in the 
widely acknowledge beneficial intervention, pulmonary rehabilitation and factors 
known to impact negatively (i.e. hospital admissions, living alone) in COPD 
populations. Interesting, only living alone came close to statistical significance. Lewis 
et al. (2007) showed statistical significance in depression scores with the addition of 
socio-demographic variables (i.e. house bound, lives alone). The lack of impact 
between attendance at pulmonary rehabilitation and the depression scores may be 
related to most of the study participants having completed the programme more than 
12 months before the research. It is generally accepted that the benefits of 
pulmonary rehabilitation wane over time (American Thoracic Society, 1999). Similar 
to this study Lacasse et al. (2001) did not find any correlations or difference between 
the depression scores and any of the demographic and clinical characteristics. 
 
An important finding of this study is that depression is undertreated and perhaps 
under recognised. This was also shown by Lacasse et al. (2001) and Lewis et al. 
(2007). It has been suggested that the issue of depression in COPD is complex due 
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to the “overlap” of the symptoms of depression and COPD (NIH, 2007; APA, 2000). 
This “overlap” suggests mood disturbance follows the functional decline seen as 
COPD progresses. Research (Coventry & Hind, 2008; Kunik et al., 2008; NZGG, 
2008) indicates that targeted interventions such as cognitive behavioural therapy, 
pulmonary rehabilitation and medications are effective in addressing depression 
symptoms in chronic obstructive pulmonary disease. Regarding the “overlap” 
pulmonary rehabilitation specifically addresses the pulmonary and extra pulmonary 
effects of chronic obstructive pulmonary disease. Treatment for depression needs to 
be targeted and a combination approach may be more beneficial for some people. 
 
As discussed in Chapter 2 there are opportunities for improved holistic care provided 
by community health services (CHS) for COPD patients. It may be earlier recognition 
of and referral for depression would improve treatment uptake. In practice, factors 
such as time constraints, patient preferences, the priorities of the nurse involved in 
the person’s care and communication problems may explain some of the limitations 
in addressing the assessment, treatment and follow-up of depression. It appears that 
isolation maybe a major interrelated factor for depression in older severe COPD 
LTOT populations, this is difficult to fully address. Although there are some options 
for social and interventional outings and increased caregiver support at home, many 
people still spend large amounts of time alone. The choice to leave one’s own 
environment and go into a rest home setting may not be an acceptable alternative for 
many people. It is also not known whether COPD LTOT patients are less depressed 
in residential facilities. As discussed in Chapter 5 the number of study participants 
living in a rest home (n=4) was too small for separate analysis and people living in 
hospital level care facilities are not part of the CHS COPD LTOT population (see 
page 3). 
 
The process regarding patients PHQ-9 results follow-up was followed according to 
the procedures detailed in the consent form and information sheet (Appendix 2 and 
3). The district nurses who work with these patients have reported that generally 
those with positive depression scores wanted to follow-up with their own general 
practitioner. At the time of writing this conclusion the researcher is not aware of the 
outcomes of this follow-up for all the patients. However, three patients are being seen 
for support more regularly by the community health service (CHS) nurses and four 
people have agreed to attend a refresher pulmonary rehabilitation programme. 
Patients that requested the overall study results have been forwarded the thesis 
abstract.  
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This study’s strengths and limitations 
Clear strengths of this current study that contribute to the validity of the results are 
that it was a total population sample and the characteristics of the population 
(responders and non-responders) were described. Additionally ethics was well 
managed, it was sufficiently powered, a validated depression screening tool was 
used, it had very complete data and a systematic approach to the data analysis were 
undertaken. 
 
Using a delivered freely available (i.e. on line) self-completed depression tool is open 
to reporting bias. This was considered and partially addressed by statements in the 
participant information and consent forms, which aimed to ease concerns a person 
may have had about reporting depression symptoms. Any bias of this study’s design 
needs to be balanced with the simplicity of administration, low cost and the 
prevention of interviewer bias.  
 
LTOT has been shown to have physiological benefits and improve neuropsychiatric 
functioning in COPD patients (Balter et al., 2002; Weidzeicha, 2000; MRC, 1981; 
NOTT, 1980). This study identified that a significant number of the participants were 
not adherent to their oxygen prescriptions. A retrospective CHS notes review was not 
conducted to check the last recorded pulse oximetry result (oxygen saturations) and 
due to the nature of the study’s design a pulse oximetry was not done at the point of 
data collection. Because of these factors it cannot be guaranteed that all hypoxia was 
corrected at the time of the PHQ-9 assessment. However, no research to date has 
provided sufficient evidence about the impacts of short periods of hypoxia for people 
receiving long term oxygen therapy. People with chronic hypoxia who are not using 
their oxygen for over 15 hours per day are not likely to benefit in terms of reduced 
premature mortality (MRC, 1981, NOTT, 1980).  
RECOMMENDATIONS FOR RESEARCH AND PRACTICE 
The PHQ-9 should be used for future research examining the prevalence of 
depression amongst people with COPD and other long-term conditions in NZ to 
determine homogeneity of studies. The study’s high response rate and complete data 
provides evidence that people found the screening tool acceptable and simple to 
complete. 
 
Portable oxygen is on the agenda for LTOT patients, service providers and 
researchers. Although this study’s results did not show any clear correlations in 
depression scores for those who have portable oxygen and those that do not, fewer 
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than 30% of the study participants reported they had access to portable oxygen and 
several commented they would like to have it. In practice portable oxygen is often 
requested by patients and families. It can be provided for attending special social 
functions or appointments but is not given routinely to all LTOT patients.  
 
The National Heart, Lung, and Blood Institute (NHLBI) working group have published 
a report that outlines recommendations for future research relating to LTOT 
treatment in COPD. This report states that a randomised double–blinded efficacy trial 
to test the hypothesis that clinical outcomes are better for those who receive oxygen 
during activity compared to those who don’t is a very high priority (Croxton & Bailey, 
2006). Nevertheless, the provision of portable oxygen is becoming more standard as 
part of the package support for people on LTOT. Current national and international 
published guidelines (NIH, 2007; Wedzicha & Calvery, 2006; Young, Crockett, & 
McDonald, 2005) are beginning to reflect and guide this. In light of the study findings 
the researcher has reviewed the local oxygen policy to include the prerequisites for 
the supply of portable oxygen. Through consultation with other specialists the DHB 
has extended the provision of portable oxygen based on a clinical assessment 
carried out in conjunction with pulmonary rehabilitation. Light weight portable oxygen 
devices are now available for people who are significantly hypoxic with activity, are 
active and spend significant amounts of time outside the house for example people 
that work. This would appear to be appropriate given that this study has identified 
that 10% of the local population is <60 years old. 
 
The level of depression in this population prior to commencing oxygen is not known. 
It is also not known whether starting oxygen early in the course of COPD, before 
permanent physiological changes occur would make a difference in health outcomes. 
Until such interventions are examined, strategies that improve the recognition and 
treatment of depression in this population should be the main concern for those 
caring for people with COPD on long term oxygen therapy. Research using the PHQ-
9 screening tool pre and post the introduction of LTOT may be valuable. However, in 
practice generally people with severe COPD are commenced on LTOT, often 
following a hospital admission. Pre and post prevalence research would be complex 
unless COPD patients were routinely screened for depression in a primary care 
setting. It would potentially require a long time frame and involve intermittently 
screening a large number of patients with the PHQ-9 and then if and when they are 
commenced on LTOT (not all people with COPD go onto meet the criteria for LTOT) 
re screening them. 
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Community nurses providing home care for people with complex long term conditions 
are well placed to add the PHQ-9 questionnaire to their tool kit of assessments to 
guide referral and care planning. This study had a high response rate suggesting 
very high acceptability of being screened for depression. However, the results also 
indicated a third of people may not want to complete such a screening tool in practice 
if the results were going to be discussed with their general practitioner. The PHQ-9 
would need a carefully planned introduction into practice to ensure it becomes 
acceptable to people. The researcher recommends the PHQ-9 should be offered and 
completed with consent on all COPD LTOT patients three months (to allow time to 
get used of the oxygen) after referral to the service. This would give a base line result 
that can be used as a vehicle for discussion with a patient, communication with the 
general practitioner (GP) and consideration of any other appropriate multidisciplinary 
interventions, such as pulmonary rehabilitation. Additionally, early recognition and 
treatment of depression may improve a person’s adherence to their long term oxygen 
therapy prescription. The benefit for patients of routine screening of depression is an 
area that requires evaluation. It is recommended that the Community Health Service 
(CHS) complete an evaluation when the PHQ-9 is introduced through a retrospective 
notes review. Documentation showing referral for GP follow-up, any treatment 
commenced as a result of screening, comments from conversations with patients, 
improved adherence to LTOT and repeat PHQ-9 scores indicating no or less 
depression symptoms could provide evidence about the impact of routine screening.  
 
CONCLUSION 
This study provides new evidence regarding the prevalence of depression in NZ 
COPD LTOT populations. It provides further evidence that depressive symptoms and 
moderate to severe depression are highly prevalent in patients with COPD on long 
term oxygen therapy. There is evidence that depression is under treated in this 
population. As COPD best practice guidelines are updated, providing more specific 
pathways to guide the screening, treatment and referral of depression in people with 
COPD would be beneficial to steer best practice. 
 
This study provides verification regarding the usability and acceptability of the PHQ-9 
depression questionnaire for people with COPD long term oxygen therapy. This 
study has informed two main recommendations. Firstly, the PHQ-9 should be used in 
future research examining the prevalence of depression in people with COPD and 
other long-term conditions. Secondly, the PHQ-9 screening tool should be included in 
the tool kit of validated instruments used by community nurses to guide the care of 
people with COPD on long term oxygen therapy. 
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APPENDICES 
 
Appendix 1: Ethics approval 
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Appendix 2: Consent form 
                                            
               Consent Form  
 What is the prevalence of depression for people with Chronic Obstructive 
Pulmonary Disease (COPD) who are on Long Term Oxygen Therapy?  
 
English 
 
I wish to have an interpreter. Yes No 
Māori 
 
E hiahia ana ahau ki tetahi kaiwhakaMāori/kaiwhaka pakeha 
korero. 
Ae Kao 
Cook Island Ka inangaro au i  tetai tangata uri reo. Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean 
 
Fia manako au ke fakaaoga e taha tagata fakahokohoko kupu. E Nakai 
Samoan 
 
Ou te mana’o ia i ai se fa’amatala upu. Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki na 
gagana o na motu o te Pahefika 
Ioe Leai 
Tongan 
 
Oku ou fiema’u ha fakatonulea. Io Ikai 
I have read and I understand the information sheet dated 16.06.09 for volunteers 
taking part in the study designed to find out the rate of depression for people 
with Chronic Obstructive Pulmonary Disease (COPD) who are on Long Term 
Oxygen Therapy.  
 
I have had the opportunity to discuss this study.  I am satisfied with the answers 
I have been given. 
 
I have had the opportunity to use whanau support or a friend to help me ask 
questions and understand the study. 
 
I understand that taking part in this study is voluntary (my choice) and that I 
may withdraw from the study at any time and this will in no way affect my 
continuing health care. 
 
I understand that my participation in this study is confidential and that no 
material which could identify me will be used in any reports on this study. 
 
I have had time to consider whether to take part. 
I agree to my depression questionnaire results being sent to my GP.       
YES/NO 
I would like a Nurse to discuss the overall outcomes of the study with me.    
YES/NO 
 I __________________________________     (full name) hereby consent to take part 
in this study.   
     Signature _____________________                             Date_______________ 
  
        Project explained by ____________________________                             
        Signature _______________________                         Date __________________ 
 
 
Page 1 of 1        Consent form for prevalence study   Version 3 approved 1.07.09 
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Appendix 3: Participant Information sheet                                                                           
                                
      
                             
                        Information Sheet  
What is the prevalence of depression for people with Chronic 
Obstructive Pulmonary Disease (COPD) who are on Long Term 
Oxygen Therapy? 
       
          Introduction 
  
You are invited to take part in this study looking at the rate of depression 
for people with COPD who are on Long Term Oxygen Therapy being 
conducted by Emma Mold. This study will be written up as a thesis as part 
of a masters in nursing and is supported by Dr Katherine Nelson Senior 
Lecturer and Alan Shaw Lecturer from Victoria University of Wellington. 
 
There is some evidence that depression is not sufficiently recognised in 
people with long-term breathing problems. This study aims to determine 
the rate and understand the extent of depression, to better inform health 
services and the type of support provided for people on long term oxygen.  
 
Ethics approval has been granted for this study by the Central Region 
Ethics Committee of New Zealand. 
 
Who and what is involved?      
      
• All people with COPD on long term oxygen throughout the Wellington 
region will be invited to participate.  
 
• If you need an interpreter one can be provided. 
 
• You are asked to fill in two short questionnaires for this study. One is a 
general individual information questionnaire and the second is a 
questionnaire (PHQ-9) to assess for depression. The PHQ-9 is a 
screening questionnaire only and positive results would not necessarily 
mean you have depression.  
 
• The questionnaires will take 10-15 minutes in total for you to complete. 
You do not have to answer all the questions.  
 
• Once you have completed your questionnaires you can post them back in 
the stamped envelope provided or arrange with your nurse to have them 
collected.   
 
• No material which could personally identify you will be used in any 
reports on this study.     
 
Page 1 of 2                                    Information sheet for prevalence study     
Version 2    Approved 16.06.09   
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•   Your participation is entirely voluntary (your choice). You do not have to 
take part in this study, and if you choose not to take part you will receive 
the usual care.  If you do agree to take part you are free to withdraw from 
the study at any time, without having to give a reason and this will in no 
way affect your continuing health care.  
 
What happens to the results? 
 
• Your own consent form and questionnaires will be filed in your hospital 
record.  
 
• With your consent, the results of your depression questionnaire will be 
forwarded to your GP. 
 
• The nurse will follow-up with you about the depression questionnaire 
results if your answers indicate you may have depression. 
 
• All computerised research information will be stored in a password 
protected computer file for 5 years.  
 
• The overall results of the research will be written as a thesis lodged at 
Victoria University library, presented at conferences and written up in a 
journal. Please note there will be a delay of up to 12 months from 
information collection and the final written thesis report. 
 
          Study and supervisor contact details:  
 
 
Dr Katherine Nelson – Research Supervisor Emma Mold- Researcher 
Graduate School of Nursing, Midwifery & Health Community Respiratory Clinical Nurse Specialist       
Victoria University of Wellington Capital Coast District Health Board 
Wellington Wellington 
kathy.nelson@vuw.ac.nz emma.mold@ccdhb.org.nz                                          
04-463 6138 04 918 6384    
 
Alan Shaw – Research Supervisor 
Graduate School of Nursing, Midwifery & Health 
Victoria University of Wellington 
Wellington 
alan.shaw@vuw.ac.nz 
04-463 6150 
 
 
 
 
 
Page 2 of 2                                    Information sheet for prevalence study     
Version 2    Approved 16.06.09   
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Appendix 4: General Practitioner letter 
 
 
 
 
OUTPATIENT LETTER 
Community Health Service 
 
 
 
Date 
 
 
RE: (inset name and NHI) 
 
 
 
Dear Dr 
 
 
(Inset patient name) was seen at home on the (insert date) and as part of a study aimed to 
determine the prevalence of depression in people with COPD on Long Term Oxygen 
Therapy. The Patient Health Questionnaire (PHQ-9) depression assessment questionnaire was 
completed.  The prevalence study is part of Emma Mold’s research for her Master of Nursing 
(Clinical) which is being undertaken under the supervision of Dr Katherine Nelson, Graduate 
School of Nursing, Midwifery and Health, Victoria University of Wellington.  
 
Please find attached (insert patient name) results for your records. 
 
The patient has been advised to see you for further assessment if their results indicate 
depression. 
 
 
 
Yours Sincerely 
 
 
Emma Mold 
Community Respiratory Nurse Clinician 
Community Health Service 
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Appendix 5: Whanau care letter 
 
08 June 2009  
 
 
Emma Mold 
Respiratory Clinical Nurse Specialist 
Community Health Services 
Capital & Coast District Health Board 
Telephone (04) 918 6384  027 479 3935 
 
 
 
Tena koe Emma  
 
 
Re: What is the prevalence of depression for people with chronic obstructive 
pulmonary disease on long term oxygen 
 
Further to our conversation about the above research proposal. You have requested 
that Whanau Care Services support the Māori participants who may be recruited for 
this study including appropriate support for themselves and their whanau.  
 
We are able to support this request if you require brochures for Whanau Care 
Services please do not hesitate to contact me.  
 
Please feel free to contact me should you have any more enquiries. 
 
 
 
 
 
Nāku noa, nā 
 
 
 
 
 
 
Helena Keyes 
Nurse Coordinator 
Whanau Care Services  
CCDHB  
04 3855956 
Helena.keyes@ccdhb.org.nz 
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Appendix 6: Developed patient questionnaire 
 
Thank you for agreeing to take part in this research 
There are 2 questionnaires attached for you to complete 
1. Name__________________________________  
2. Age______________     
3. Gender: Male    Female   
 
4. Please indicate which ethnic group(s) you identify with. Tick as many as are 
applicable 
[     ] NZ European      
[     ] Māori 
[     ] Pacific Island 
[     ] Asian 
[     ] Other (please describe) __________________       
  
5. What is your employment status (e.g. retired, unemployed, paid work (part time / 
fulltime)? 
               ______________________________________________________ 
 
6. Do you live alone?                                                                           Yes    No    
 
 
7. How many hours each day do you use your home oxygen? Tick one 
[     ] Less than 5 hours a day 
[     ] 5 - 9 hours 
[     ] 10 - 14 hours 
[     ] 15 - 19 hours 
[     ] 20 or more hours 
Please comment on your home oxygen use if you wish 
_____________________________________________________________________
_____________________________________________________________________ 
8. Do you have a small portable oxygen cylinder to use outside the 
         house (e.g. for shopping, regular social events or work)?              Yes    No    
 
9. Have you completed the ‘Pulmonary Rehabilitation Programme’ 
        run by the hospital?               Yes    No   Don’t know  
 
         If YES, how long ago did you do the programme? ______________ 
 
10. Have you ever been told by a health professional you have depression? Yes  No    
                                                                                        
 
11. Are you currently being treated for depression?                               Yes    No    
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Appendix 7: The nine questions of the PHQ-9 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems? 
(not at all = 0, several days = 1, more than half the days = 2, nearly every day = 3) 
1. Little interest or pleasure in doing things? 
2. Feeling down, depressed, or hopeless?  
3. Trouble falling or staying asleep, or sleeping too much? 
 
4. Feeling tired or having little energy? 
5. Poor appetite or overeating?  
6. Feeling bad about yourself - or that you are a failure or have let yourself or 
your family down? 
 
7. Trouble concentrating on things, such as reading the newspaper or watching 
television? 
 
8. Moving or speaking so slowly that other people could have noticed? 
Or the opposite - being so fidgety or restless that you have been moving 
around a lot more than usual? 
 
9. Thoughts that you would be better off dead, or of hurting yourself in some 
way?  
 
Total score = number/27 
 
Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately 
severe, 20-27 severe. 
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Appendix 8: Coding sheet 
 
Prevalence of depression amongst people with COPD on LTOT  
Q. No Variable Variable Values Variable type 
 No As per questionnaire Nominal 
 Surveyed 1. Yes 
2. No 
Nominal 
A Age In years Scale 
B Gender 1.  Male 
2.  Female 
Nominal 
C Ethnicity 1. Māori ONLY 
2. European ONLY 
3. Pacific ONLY 
4. Asian ONLY 
5. Other ONLY 
6. Māori AND European 
7. Māori AND Pacific 
Nominal 
D Employment 1. Retired 
2. Paid work 
3. Unemployed 
4. Other benefit 
5. Self employed 
Nominal 
E Lives alone 1. Yes 
2. No 
Nominal 
F FEV1   FEV1 as a percentage Scale 
G O2 months on In months Scale 
H O2 Rx 1. 16 / 16+ hours 
2. 24 hours 
3. PRN 
4. Nocturnal 
Nominal 
I O2 Usage 1. < 5 hours 
2. 5-9 
3. 10-14 
4. 15-19 
5. 20 or more 
Ordinal  
J Portable 1. Yes 
2. No  
Nominal 
K Prehab 1. Yes 
2. No 
3. Don’t know 
Nominal 
L Prehab when In months Scale 
M Depever 1. Yes 
2. No 
Nominal 
N DepRx 1. Yes 
2. No 
Nominal 
O PHQ-9       Total score (0-27) Scale 
P PHQ-9scale 1. None (0-4) 
2. Mild (5-9) 
3. Moderate (10-14) 
4. Moderately severe (15-19) 
5. Severe (20-27) 
Ordinal  
 Admissions  Number of admissions Scale 
 LOS Total inpatient days Scale 
  88. Missing data 
99. n/a data 
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